WO1993007149A1 - Pyrazolopyrimidinone antianginal agents - Google Patents
Pyrazolopyrimidinone antianginal agents Download PDFInfo
- Publication number
- WO1993007149A1 WO1993007149A1 PCT/EP1992/002237 EP9202237W WO9307149A1 WO 1993007149 A1 WO1993007149 A1 WO 1993007149A1 EP 9202237 W EP9202237 W EP 9202237W WO 9307149 A1 WO9307149 A1 WO 9307149A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- alkyl
- methyl
- propyl
- reaction
- Prior art date
Links
- YCIMNLLNPGFGHC-UHFFFAOYSA-N Oc1ccccc1O Chemical compound Oc1ccccc1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Definitions
- This invention relates to a series of
- pyrazolo[3,4-d]pyrimidin-4-ones which are potent and selective inhibitors of cyclic guanosine 3',5'- monophosphate phosphodiesterase (cGMP PDE), having utility in a variety of therapeutic areas including the treatment of cardiovascular disorders such as angina, hypertension, heart failure and atherosclerosis.
- cGMP PDE cyclic guanosine 3',5'- monophosphate phosphodiesterase
- the compounds of the invention exhibit selectivity for inhibition of cGMP PDEs rather than cyclic
- cAMP PDEs adenosine 3' ,5'-monophosphate phosphodiesterases
- EDRF endothelium-derived relaxing factor
- the compounds have utility in the treatment of a number of disorders, including stable, unstable and variant (Prinzmetal) angina, hypertension, pulmonary hypertension, congestive heart failure,
- Atherosclerosis conditions of reduced blood vessel patency e.g. post-percutaneous transluminal coronary angioplasty (post-PTCA), peripheral vascular disease, stroke, bronchitis, chronic asthma, allergic rhinitis, glaucoma, and diseases characterised by disorders of gut motility, e.g. irritable bowel syndrome (IBS).
- post-PTCA post-percutaneous transluminal coronary angioplasty
- peripheral vascular disease e.g. post-percutaneous transluminal coronary angioplasty (post-PTCA)
- stroke bronchitis
- chronic asthma e.g. chronic asthma
- allergic rhinitis glaucoma
- glaucoma irritable bowel syndrome
- European patent application EP-A-0349239 discloses a group of 1-unsubstituted pyrazolo[3,4-d]pyrimidin-4-ones as cGMP PDE inhibitors with bronchodilator and vasodilator activity of value in combatting asthma, bronchitis, angina, hypertension and congestive heart failure.
- EP-A-0201188 discloses certain pyrazolo[4,3-d]pyrimidin-7-ones as adenosine receptor antagonists and PDE inhibitors, useful in the treatment of cardiovascular disorders such as heart failure or cardiac insufficiency. However these compounds are neither particularly potent PDE
- the compounds of the present invention have the formula (I):
- R 1 is C 1 -C 6 alkyl
- R 2 is H, methyl or ethyl
- R 3 is C 2 -C 4 alkyl
- R 4 is C r -C 4 alkyl optionally substituted with NR 5 R 6 , CN, CONR 5 R 6 or CO 2 R 7 ; C 2 -C 4 alkenyl optionally substituted with CN, CONR 5 R 6 or CO 2 R 7 ; C 2 -C 4 alkanoyl optionally substituted with NR 5 R 6 ; SO 2 NR 5 R 6 ; CONR 5 R 6 ; CO 2 R 7 ; or halo; R 5 and R 6 are each independently H or C 1 -C 4 alkyl, or together with the nitrogen atom to which they are attached form a pyrrolidino, piperidino, morpholino, 4-(NR 8 )-1-piperazinyl or 1-imidazolyl group wherein said group is optionally substituted by one or two C 1 -C 4 alkyl groups;
- R 7 is H or C 1 -C 4 alkyl
- R 8 is H, C 1 -C 3 alkyl or hydroxy C 2 -C 3 alkyl; and pharmaceutically acceptable salts thereof.
- alkyl and alkoxy groups having three or more carbon atoms may be straight chain or branched chain.
- alkenyl and alkanoyl groups having four carbon atoms may be straight chain or branched chain.
- Halo means fluoro, chloro, bromo or iodo.
- the compounds of formula (I) may contain one or more asymmetric centres and thus they can exist as enantiomers or diastereoisomers. Furthermore certain compounds of formula (I) which contain alkenyl groups may exist as cis- or trans-isomers. In each instance, the invention includes both mixtures and separate individual isomers.
- the compounds of formula (I) may also exist in tautomeric forms and the invention includes both mixtures and separate individual tautomers.
- radiolabelled derivatives of compounds of formula (I) which are suitable for biological studies.
- the pharmaceutically acceptable salts of the compounds of formula (I) which contain a basic centre are acid addition salts formed with pharmaceutically acceptable acids.
- examples include the hydrochloride, hydrobromide, sulphate or bisulphate, phosphate or hydrogen phosphate, acetate, benzoate, succinate, fumarate, maleate, lactate, citrate, tartrate,
- Compounds of the formula (I) can also provide pharmaceutically acceptable metal salts, in particular alkali metal salts, with bases. Examples include the sodium and potassium salts.
- a preferred group of compounds of formula (I) is that wherein R 1 is n-propyl; R 2 is H or methyl; R 3 is ethyl or n-propyl; R 4 is ethyl substituted with CONR 5 R 6 or CO 2 R 7 ; vinyl substituted with CONR 5 R 6 or CO 2 R 7 ; acetyl substituted with NR 5 R 6 ; SO 2 NR 5 R 6 ; CONR 5 R 6 ; CO 2 R 7 ; or bromo; R 5 and R 6 together with the nitrogen atom to which they are attached form a morpholino, 4-(NR 8 )-1- piperazinyl or 2, 4-dimethyl-1-imidazolyl group; R 7 is H or t-butyl; and R 8 is methyl or 2-hydroxyethyl.
- Particularly preferred individual compounds of the invention include:
- the compounds of formula (I) may be prepared by a variety of methods from a compound of formula (II):
- R 1 , R 2 and R 3 are as previously defined for formula (I).
- R 4 is C 2 -C 4 alkanoyl
- the required product is obtainable by conventional Friedel-Crafts acylation whereby (II) is reacted with about a 2-fold excess of an acyl halide of formula (C 1 - C 3 alkyl) COY, wherein Y is halo, preferably chloro or bromo, in the presence of about a 3-fold excess of a Lewis acid such as aluminium chloride or aluminium bromide, in a suitable solvent, e.g. dichloromethane, at from about 0°C to the reflux temperature of the reaction medium.
- a suitable solvent e.g. dichloromethane
- R 4 is C 2 -C 4 alkanoyl substituted with NR 5 R 6 , wherein R 5 and R 6 are as previously defined
- the product is obtained from (II) via the intermediacy of the corresponding haloketone, i.e. a compound of formula (I) wherein R 4 is CO(C 1 -C 3 alkylene)X and X is halo, preferably chloro or bromo, by reaction of the appropriate haloketone with the required amine of formula R 5 R 6 NH in the presence of at least one
- the base may be an
- inorganic salt such as anhydrous potassium carbonate, a tertiary amine such as triethylamine, or excess
- protecting group e.g. benzyl which can be subsequently removed by catalytic hydrogenation.
- R 5 and R 6 are H
- the potassium salt of the non-basic aminating reagent is used for reaction with the haloketone; deprotection is effected by acidolysis using, for example, hydrogen chloride, which allows convenient isolation of the desired aminoketone as its hydrochloric salt.
- the intermediate haloketone is also obtained via Friedel-Crafts chemistry, as described above, in this case between (II) and the appropriate haloacyl halide of formula X(C 1 -C 3 alkylene)COY, wherein X and Y are as previously defined.
- the primary amines are obtained by nitration of (II) using, e.g. a conventional
- (II), i.e. compounds of formula (III), may also be, prepared directly from compounds of formula (II) by bromination in a suitable solvent. This may be
- the reaction is generally carried out with about a 50% excess of both the alkene reagent and a tertiary amine such as triethylamine, in the presence of about 0.1 equivalents of a tertiary
- arylphosphine preferably tri-o-tolylphosphine, and about 0.05 equivalents of palladium(II) acetate, in a suitable solvent such as acetonitrile, at the reflux temperature of the reaction medium.
- a suitable solvent such as acetonitrile
- the resulting acrylic esters may be hydrolysed if desired, e.g. using aqueous sodium hydroxide solution, with methanol as co-solvent, to afford the corresponding cinnamic acids.
- these cinnamic acids may be used as an
- paraformaldehyde and concentrated hydrochloric acid at from about room temperature to about 120°C.
- the desired alkenes (and derived alkanes via catalytic hydrogenation) may be obtained using a Wittig-Horner strategy in which an aldehyde of formula (I), wherein R 4 is CHO and R 1 , R 2 and R 3 are as previously defined, is reacted with the appropriate phosphonium salt or phosphonate in the presence of a suitable base.
- the aldehyde itself is obtainable by formylation, e.g. using DMF, of the aryllithium
- the chloromethyl intermediates of formula (IV) may also be used for the preparation of compounds of formula (I), wherein R 4 is CH 2 NR 5 R 6 and R 1 , R 2 , R 3 , R 5 and R 6 are as previously defined, by reaction with the appropriate amine of formula HNR 5 R 6 (or protected version thereof - vide supra). Preferably the reaction is carried out with about a 3-fold excess of amine in a suitable solvent, e.g. 2-butanone, at from about 0°C to the reflux temperature of the reaction medium.
- a suitable solvent e.g. 2-butanone
- compounds of formula (I) wherein R 4 is (C 2 -C 4 alkylene)NR 5 R 6 may be conveniently obtained from, e.g., the appropriate chloro, bromo, iodo or mesyloxy
- the C 2 -alcohol (R 4 is CH 2 CH 2 OH) may be obtained by reaction of the above-mentioned aryllithium
- aryllithium intermediates are also useful in the preparation of compounds of formula (I) wherein R 4 is CONR 5 R 6 or CO 2 R 7 and R 1 , R 2 , R 3 , R 5 , R 6 and R 7 are as previously defined.
- R 4 is CONR 5 R 6 or CO 2 R 7 and R 1 , R 2 , R 3 , R 5 , R 6 and R 7 are as previously defined.
- lithiation of (III) in dry tetrahydrofuran (THF) at about -78°C using about a 2 to 3-fold excess of a solution of n-butyllithium in hexane, quenching of the resulting aryllithium with carbon dioxide at from about -70 to 0°C, and aqueous acidic work-up at about room temperature furnishes the corresponding benzoic acid derivative.
- the acid may be activated under mild conditions, such as those
- R 1 , R 2 and R 3 are as previously defined for formula (IV), and Z is fluoro, chloro or bromo, preferably chloro, with a compound of formula (VI):
- reaction is generally carried out at room temperature, preferably in the presence of a solvent, for example a C 1 -C 3 alkanol, using a 2 to 5-fold excess of (VI) to scavenge the acid by-product (HZ).
- a solvent for example a C 1 -C 3 alkanol
- the cyclisation may be effected by the treatment of (VII) with a base such as sodium hydroxide or potassium carbonate, optionally in the presence of hydrogen peroxide, in an ethanol-water medium at reflux
- compounds of the formula (II) may be obtained by treatment of (VII) with polyphosphoric acid at about 140°C.
- R 3 and Y are as previously defined.
- the reaction is generally carried out using about a 20% excess of (X) in the presence of an excess of a tertiary amine such as triethylamine or pyridine to act as scavenger for the acid by-product (HY), optionally in the presence of a catalyst such as 4-dimethylamino-pyridine, in an inert solvent such as dichloromethane at from about 0 to about 25°C for 2-24 hours.
- a catalyst such as 4-dimethylamino-pyridine
- an inert solvent such as dichloromethane at from about 0 to about 25°C for 2-24 hours.
- pyridine may also be used as solvent.
- aminopyrazole carboxamides of formula (VIII) may be obtained by acid hydrolysis of the corresponding nitriles of formula (IX), whilst the latter, the acyl halides of formulae (X) and (XI), and the intermediates employed for introduction of the various R 4
- the pharmaceutically acceptable acid addition salts of the compounds of formula (I) which contain a basic centre may also be prepared in a conventional manner.
- a solution of the free base is treated with the appropriate acid, either neat or in a suitable solvent, and the resulting salt isolated either by filtration or by evaporation under vacuum of the reaction solvent.
- Pharmaceutically acceptable base addition salts can be obtained in an analogous manner by treating a solution of a compound of formula (I) with the appropriate base. Both types of salt may be formed or interconverted using ion-exchange resin techniques.
- the biological activities of the compounds of the present invention were determined by the following test methods.
- Compound affinities for cGMP and cAMP PDEs are assessed by determination of their IC 50 values (the concentration of inhibitor required for 50% inhibition of enzyme activity).
- the PDE enzymes are isolated from rabbit platelets and rat kidney, essentially by the method of W.J. Thompson et al.. (Biochem., 1971, 10, 311).
- the calcium/calmodulin (Ca/CAM)-independent cGMP PDE and the cGMP-inhibited cAMP PDE enzymes are
- Washed platelets are prepared essentially by the method of J.F. Mustard et al.
- oral dosages of the compounds will generally be in the range of from 4-800 mg daily for an average adult patient (70 kg).
- individual tablets or capsules contain from 2-400 mg of active compound, in a suitable
- dosages for intravenous, buccal or sublingual administration will typically be within the range of from 1-400 mg per single dose as required.
- physician will determine the actual dosing regimen which will be most suitable for an individual patient and it will vary with the age, weight and response of the particular patient.
- the above dosages are exemplary of the average case but there can be individual instances in which higher or lower dosage ranges may be merited, and such are within the scope of this invention.
- the compounds of the formula (I) can be administered alone, but will generally be administered in admixture with a pharmaceutical carrier selected with regard to the intended route of
- compositions for example, they may be administered orally, buccally or sublingually, in the form of tablets containing excipients such as starch or lactose, or in capsules or ovules either alone or in admixture with excipients, or in the form of elixirs or suspensions containing
- flavouring or colouring agents may also be injected parenterally, for example intravenously, intramuscularly, subcutaneously or intracoronarily.
- a sterile aqueous solution which may
- the invention provides a pharmaceutical composition
- a pharmaceutical composition comprising a compound of the formula (I), or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable diluent or carrier.
- the invention also provides a compound of the formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing either entity, for use in medicine.
- the invention further provides the use of a compound of the formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical
- the invention provides a method of treating or preventing stable, unstable and variant (Prinzmetal) angina, hypertension, pulmonary hypertension, congestive heart failure,
- Atherosclerosis stroke, peripheral vascular disease, conditions of reduced blood vessel patency e.g. post-PTCA, chronic asthma, bronchitis, allergic asthma, allergic rhinitis, glaucoma, or diseases characterised by disorders of gut motility, e.g. IBS, in a mammal (including a human being) which comprises administering to said mammal a therapeutically effective amount of a compound of formula (I), or a pharmaceutically
- composition containing either entity.
- the invention also includes any novel
- Morpholine (0.175 g, 0.002 mol) was added to a stirred suspension of 6-(5-bromoacetyl-2-ethoxyphenyl)- 1-n-propyl-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4- one (Preparation 4; 0.70 g, 0.0017 mol) and anhydrous potassium carbonate (0.461 g, 0.0033 mol) in
- Aluminium trichloride (1.34 g, 0.010 mol) was added portionwise to a stirred solution of 6-(2-ethoxyphenyl)-1-n-propyl-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (Example 1; 1.0 g, 0.0034 mol) and bromoacetyl bromide (1.35, 0.0067 mol) in
- Example 3 has been tested at therapeutic doses of up to 1 mg/Kg i.v. in rabbit with no signs of adverse acute toxicity being observed.
Abstract
Compounds of formula (I), and pharmaceutically acceptable salts thereof wherein R1 is C1-C6 alkyl; R2 is H, methyl or ethyl; R3 is C2-C4 alkyl; R4 is C1-C4 alkyl optionally substituted with NR5R6, CN, CONR5R6 or CO¿2R?7; C2-C4 alkenyl optionally substituted with CN, CONR5R6 or CO¿2R?7; C2-C4 alkanoyl optionally substituted with NR5R6; SO2NR?5R6; CONR5R6; CO¿2R7; or halo; R?5 and R6¿ are each independently H or C¿1?-C4 alkyl, or together with the nitrogen atom to which they are attached form a pyrrolidino, piperidino, morpholino, 4-(NR?8¿)-1-piperazinyl or 1-imidazolyl group wherein said group is optionally substituted by one or two C¿1?-C4 alkyl groups; R?7¿ is H or C¿1?-C4 alkyl; and R?8¿ is H, C¿1?-C3 alkyl or hydroxy C2-C3 alkyl; are selective cGMP PDE inhibitors useful in the treatment of cardiovascular disorders such as angina hypertension, heart failure and atherosclerosis.
Description
PYRAZOLOPYRIMIDINONE ANTIANGINAL AGENTS
This invention relates to a series of
pyrazolo[3,4-d]pyrimidin-4-ones, which are potent and selective inhibitors of cyclic guanosine 3',5'- monophosphate phosphodiesterase (cGMP PDE), having utility in a variety of therapeutic areas including the treatment of cardiovascular disorders such as angina, hypertension, heart failure and atherosclerosis.
The compounds of the invention exhibit selectivity for inhibition of cGMP PDEs rather than cyclic
adenosine 3' ,5'-monophosphate phosphodiesterases (cAMP PDEs) and, as a consequence of this selective PDE inhibition, cGMP levels are elevated, which in turn can give rise to beneficial anti-platelet, anti-neutrophil, anti-vasospastic and vasodilatory activity, as well as potentiation of the effects of endothelium-derived relaxing factor (EDRF) and nitrovasodilators. Thus the compounds have utility in the treatment of a number of disorders, including stable, unstable and variant (Prinzmetal) angina, hypertension, pulmonary hypertension, congestive heart failure,
atherosclerosis, conditions of reduced blood vessel patency e.g. post-percutaneous transluminal coronary angioplasty (post-PTCA), peripheral vascular disease, stroke, bronchitis, chronic asthma, allergic rhinitis, glaucoma, and diseases characterised by disorders of gut motility, e.g. irritable bowel syndrome (IBS).
European patent application EP-A-0349239 discloses a group of 1-unsubstituted pyrazolo[3,4-d]pyrimidin-4-ones as cGMP PDE inhibitors with bronchodilator and vasodilator activity of value in combatting asthma, bronchitis, angina, hypertension and congestive heart failure.
European patent application EP-A-0201188 discloses certain pyrazolo[4,3-d]pyrimidin-7-ones as adenosine receptor antagonists and PDE inhibitors, useful in the treatment of cardiovascular disorders such as heart
failure or cardiac insufficiency. However these compounds are neither particularly potent PDE
inhibitors, nor are they claimed to be selective inhibitors of cGMP PDE.
The compounds of the present invention have the formula (I):
R2 is H, methyl or ethyl;
R3 is C2-C4 alkyl;
R4 is Cr-C4 alkyl optionally substituted with NR5R6, CN, CONR5R6 or CO2R7; C2-C4 alkenyl optionally substituted with CN, CONR5R6 or CO2R7; C2-C4 alkanoyl optionally substituted with NR5R6; SO2NR5R6; CONR5R6; CO2R7; or halo; R5 and R6 are each independently H or C1-C4 alkyl, or together with the nitrogen atom to which they are attached form a pyrrolidino, piperidino, morpholino, 4-(NR8)-1-piperazinyl or 1-imidazolyl group wherein said group is optionally substituted by one or two C1-C4 alkyl groups;
R7 is H or C1-C4 alkyl;
and R8 is H, C1-C3 alkyl or hydroxy C2-C3 alkyl; and pharmaceutically acceptable salts thereof.
In the above definition, unless otherwise
indicated, alkyl and alkoxy groups having three or more
carbon atoms may be straight chain or branched chain. In addition, alkenyl and alkanoyl groups having four carbon atoms may be straight chain or branched chain. Halo means fluoro, chloro, bromo or iodo.
The compounds of formula (I) may contain one or more asymmetric centres and thus they can exist as enantiomers or diastereoisomers. Furthermore certain compounds of formula (I) which contain alkenyl groups may exist as cis- or trans-isomers. In each instance, the invention includes both mixtures and separate individual isomers.
The compounds of formula (I) may also exist in tautomeric forms and the invention includes both mixtures and separate individual tautomers.
Also included in the invention are radiolabelled derivatives of compounds of formula (I) which are suitable for biological studies.
The pharmaceutically acceptable salts of the compounds of formula (I) which contain a basic centre are acid addition salts formed with pharmaceutically acceptable acids. Examples include the hydrochloride, hydrobromide, sulphate or bisulphate, phosphate or hydrogen phosphate, acetate, benzoate, succinate, fumarate, maleate, lactate, citrate, tartrate,
gluconate, methanesulphonate, benzenesulphonate and p-toluenesulphonate salts. Compounds of the formula (I) can also provide pharmaceutically acceptable metal salts, in particular alkali metal salts, with bases. Examples include the sodium and potassium salts.
A preferred group of compounds of formula (I) is that wherein R1 is n-propyl; R2 is H or methyl; R3 is ethyl or n-propyl; R4 is ethyl substituted with CONR5R6 or CO2R7; vinyl substituted with CONR5R6 or CO2R7; acetyl substituted with NR5R6; SO2NR5R6; CONR5R6; CO2R7; or bromo; R5 and R6 together with the nitrogen atom to
which they are attached form a morpholino, 4-(NR8)-1- piperazinyl or 2, 4-dimethyl-1-imidazolyl group; R7 is H or t-butyl; and R8 is methyl or 2-hydroxyethyl.
Particularly preferred individual compounds of the invention include:
6-(5-bromo-2-n-propoxyphenyl)-3-methyl-1-n-propyl- 1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one;
3-methyl-6-(5-morpholinosulphonyl-2-n- propoxyphenyl)-1-n-propyl-1,5-dihydro-4H-pyrazolo[3,4- d]pyrimidin-4-one;
6-[5-(2-carboxyvinyl)-2-n-propoxyphenyl]-3-methyl- 1-n-propyl-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4- one;
6-[5-(2-t-butoxycarbonylvinyl)-2-n-propoxyphenyl]- 3-methyl-1-n-propyl-1,5-dihydro-4H-pyrazolo[3,4- d]pyrimidin-4-one;
3-methyl-6-[5-(2-morpholinocarbonylvinyl)-2-n- propoxyphenyl]-1-n-propyl-1,5-dihydro-4H-pyrazolo[3,4- d]pyrimidin-4-one;
and 3-methyl-6-[5-(2-morpholinocarbonylethyl)-2-n- propoxyphenyl]-1-n-propyl-1,5-dihydro-4H-pyrazolo[3,4- d]pyrimidin-4-one.
Depending on the nature of R4, the compounds of formula (I) may be prepared by a variety of methods from a compound of formula (II):
wherein R1, R2 and R3 are as previously defined for
formula (I). For example, when R4 is C2-C4 alkanoyl, the required product is obtainable by conventional Friedel-Crafts acylation whereby (II) is reacted with about a 2-fold excess of an acyl halide of formula (C1- C3 alkyl) COY, wherein Y is halo, preferably chloro or bromo, in the presence of about a 3-fold excess of a Lewis acid such as aluminium chloride or aluminium bromide, in a suitable solvent, e.g. dichloromethane, at from about 0°C to the reflux temperature of the reaction medium. When R4 is C2-C4 alkanoyl substituted with NR5R6, wherein R5 and R6 are as previously defined, the product is obtained from (II) via the intermediacy of the corresponding haloketone, i.e. a compound of formula (I) wherein R4 is CO(C1-C3 alkylene)X and X is halo, preferably chloro or bromo, by reaction of the appropriate haloketone with the required amine of formula R5R6NH in the presence of at least one
equivalent of base to scavenge the liberated acid by-product (HX), in a suitable solvent, e.g. acetonitrile, at about room temperature. The base may be an
inorganic salt such as anhydrous potassium carbonate, a tertiary amine such as triethylamine, or excess
reactant amine. In cases wherein either R5 or R6 is H, it may be advantageous to use a protected amine of formula R5NHP or R6NHP wherein P is a compatible
protecting group, e.g. benzyl which can be subsequently removed by catalytic hydrogenation. When both R5 and R6 are H, an ammonia equivalent of formula P'2NH, wherein P' is a protecting group such as t-butoxycarbonyl, may be beneficially employed. In this case, the potassium salt of the non-basic aminating reagent is used for reaction with the haloketone; deprotection is effected by acidolysis using, for example, hydrogen chloride, which allows convenient isolation of the desired aminoketone as its hydrochloric salt. The intermediate haloketone is also obtained via Friedel-Crafts
chemistry, as described above, in this case between (II) and the appropriate haloacyl halide of formula X(C1-C3 alkylene)COY, wherein X and Y are as previously defined.
Compounds of formula (I) wherein R4 is halo and R1, R2 and R3 are as previously defined may be obtained from the corresponding primary amine, i.e. a compound of formula (I) wherein R4 is NH2, via classical sequential diazotisation-halogenation procedures including, for example, the Schiemann, Sandmeyer and Gatterman
reactions. The primary amines, in turn, are obtained by nitration of (II) using, e.g. a conventional
concentrated nitric acid/concentrated sulphuric acid combination, followed by reduction of the intermediate nitroarene, e.g. by catalytic hydrogenation.
Compounds of formula (I) wherein R4 is bromo, and R1, R2 and R3 are as previously defined for formula
(II), i.e. compounds of formula (III), may also be, prepared directly from compounds of formula (II) by bromination in a suitable solvent. This may be
achieved, for example, either with about a 60-100% excess of N-bromosuccinimide in dimethylformamide (DMF) at room temperature or with a similar excess of bromine in glacial acetic acid at from about room temperature to about 100°C. These bromo compounds are also
valuable intermediates in the synthesis of further
compounds of formula (I).
By exploitation of Heck methodology, the bromo intermediates (III) can be transformed to compounds of formula (I), wherein R4 is CH=CHCN, CH=CHCONR5R6 or CH=CHCO2R7 and R1, R2, R3, R5, R6 and R7 are as previously defined, except that R7 is not H, by employment of acrylonitrile or the appropriate acrylic acid amide or ester derivative. The reaction is generally carried out with about a 50% excess of both the alkene reagent and a tertiary amine such as triethylamine, in the presence of about 0.1 equivalents of a tertiary
arylphosphine, preferably tri-o-tolylphosphine, and about 0.05 equivalents of palladium(II) acetate, in a suitable solvent such as acetonitrile, at the reflux temperature of the reaction medium. The resulting acrylic esters may be hydrolysed if desired, e.g. using aqueous sodium hydroxide solution, with methanol as co-solvent, to afford the corresponding cinnamic acids. Clearly, these cinnamic acids may be used as an
alternative source of cinnamamides of formula (I) wherein R4 is CH=CHCONR5R6 via the corresponding acyl halide (preferably chloride), or other activated acid derivative, by reaction with the appropriate amine of formula HNR5R6 (vide infra). Moreover, all the alkenyl products thus synthesised may be subjected to catalytic hydrogenation, e.g. using 5-10% palladium on charcoal in a suitable solvent at about 15-50 p.s.i. (1.0-3.45 bar) and room temperature, to provide compounds of formula (I) wherein R4 is CH2CH2CN, CH2CH2CONR5R6 or
CH2CH2CO2R7 and R1, R2, R3, R5, R6 and R7 are as previously defined for formula (I). An alternative reduction strategy, in which the acrylonitrile derivative
(cinnamonitrile analogue) is exhaustively hydrogenated with Raney nickel in glacial acetic acid, affords compounds of formula (I) wherein R4 is 3-aminopropyl and R1, R2 and R3 are as previously defined.
The higher homologues, i.e. compounds of formula (I) wherein R4 is either C3-C4 alkyl or C3-C4 alkenyl substituted with CN, CONR5R6 or CO2R7, or is 4- aminobutyl, may be derived from the alkenols obtained from Heck reactions between a bromo compound of formula (III) and either allyl alcohol or 3-buten-1-ol. The conventional procedures necessary for transformation of the terminal hydroxyl group via a suitably reactive derivative, e.g. the corresponding chloride, bromide, iodide or mesylate, to the required functional groups will be well known to persons skilled in the art, and will be equally applicable to the 2-hydroxyethyl analogue(vide infra) thereby offering an alternative to Heck methodology. Compounds of formula (I), wherein R4 is CH2CN, CH2CONR5R6, CH2CO2R7 or CH2CH2NH2, may be obtained from the chloromethyl intermediates of formula (IV) by reaction with an alkali metal cyanide, e.g. sodium cyanide or potassium cyanide, followed by standard transformations of the resulting nitrile.
Compounds of formula (IV), wherein R1, R2 and R3 are as previously defined for formula (III), are
obtainable by subjecting compounds of formula (II) to standard chloromethylation conditions, e.g.
paraformaldehyde and concentrated hydrochloric acid, at from about room temperature to about 120°C.
As a general alternative to the above Heck
reaction approach, the desired alkenes (and derived
alkanes via catalytic hydrogenation) may be obtained using a Wittig-Horner strategy in which an aldehyde of formula (I), wherein R4 is CHO and R1, R2 and R3 are as previously defined, is reacted with the appropriate phosphonium salt or phosphonate in the presence of a suitable base. The aldehyde itself is obtainable by formylation, e.g. using DMF, of the aryllithium
derivative of (III) and, by analogy, is also a
convenient precursor to compounds of formula (I) wherein R4 is C2-C4 alkenyl or C2-C4 alkyl and R1, R2 and R3 are as previously defined. The aryllithium
derivative of (III) is readily preparable from (III) by lithium-bromine exchange, using n-butyllithium, under conventional conditions.
The chloromethyl intermediates of formula (IV) may also be used for the preparation of compounds of formula (I), wherein R4 is CH2NR5R6 and R1, R2, R3, R5 and R6 are as previously defined, by reaction with the appropriate amine of formula HNR5R6 (or protected version thereof - vide supra). Preferably the reaction is carried out with about a 3-fold excess of amine in a suitable solvent, e.g. 2-butanone, at from about 0°C to the reflux temperature of the reaction medium. By analogy, compounds of formula (I) wherein R4 is (C2-C4 alkylene)NR5R6 may be conveniently obtained from, e.g., the appropriate chloro, bromo, iodo or mesyloxy
precursor which, in turn, are derivable from the corresponding alcohol by standard procedures.
The C2-alcohol (R4 is CH2CH2OH) may be obtained by reaction of the above-mentioned aryllithium
intermediate with ethylene oxide, whilst the C3- and C4-alcohols can be prepared by catalytic hydrogenation of the alkenols obtained when a bromo compound of formula (III) is subjected to Heck reaction conditions with allyl alcohol or 3-buten-1-ol respectively (vide supra).
The chloromethyl intermediates (IV) may be further employed to furnish the corresponding methyl
derivatives, i.e. compounds of formula (I) wherein R4 is CH3 and R1, R2 and R3 are as previously defined. This can be achieved by catalytic hydrogenation using a palladium on charcoal catalyst, in a suitable solvent such as ethyl acetate, at about 50 p.s.i. (3.45 bar) and room temperature. By analogy, when R4 is ethyl, n- propyl or n-butyl, such compounds of formula (I) may also be obtained from the corresponding alkyl chlorides derived, in turn, from the appropriate alcohols
mentioned above by standard methodology. Other alcohol derivatives, e.g. the corresponding bromide, iodide or mesylate, may also be used.
The aryllithium intermediates are also useful in the preparation of compounds of formula (I) wherein R4 is CONR5R6 or CO2R7 and R1, R2, R3, R5, R6 and R7 are as previously defined. For example, lithiation of (III) in dry tetrahydrofuran (THF) at about -78°C using about a 2 to 3-fold excess of a solution of n-butyllithium in hexane, quenching of the resulting aryllithium with carbon dioxide at from about -70 to 0°C, and aqueous acidic work-up at about room temperature, furnishes the corresponding benzoic acid derivative. The acid may be activated under mild conditions, such as those
obtaining in peptide bond formation via amino acid coupling procedures, and converted to an ester or amide derivative as required. For example, activation of the benzoic acid using a carbodiimide/1-hydroxybenzo-triazole combination in the presence of the required amine of formula HNR5R6 or alcohol of formula R7OH, in a suitable solvent such as dichloromethane at about 0°C to room temperature, yields the corresponding amide or ester respectively. Alternatively, the acyl halide, most conveniently the acyl chloride, may be used as the required intermediate.
Compounds of the formula (I) wherein R4 is SO2NR5R6 and R1, R2, R3, R5 and R6 are as previously defined may be prepared by the reaction of a compound of formula (V):
wherein R1, R2 and R3 are as previously defined for formula (IV), and Z is fluoro, chloro or bromo, preferably chloro, with a compound of formula (VI):
HNR5R6 (VI) wherein R5 and R6 are as previously defined. The reaction is generally carried out at room temperature, preferably in the presence of a solvent, for example a C1-C3 alkanol, using a 2 to 5-fold excess of (VI) to scavenge the acid by-product (HZ).
Compounds of formula (V) are obtainable from compounds of formula (II) by the application of known methods for the introduction of a SO2Z group, wherein Z is as previously defined, into a benzene ring. For example, when Z represents a chlorine atom, by the action of chlorosulphonic acid at or near 0°C.
Compounds of formula (II) may be prepared from compounds of formula (VII):
wherein R1, R2 and R3 are as previously defined, by the application of known cyclisation methods for
pyrimidinone ring formation. Thus, for example, the cyclisation may be effected by the treatment of (VII) with a base such as sodium hydroxide or potassium carbonate, optionally in the presence of hydrogen peroxide, in an ethanol-water medium at reflux
temperature.
In an alternative cyclisation procedure, compounds of the formula (II) may be obtained by treatment of (VII) with polyphosphoric acid at about 140°C.
Compounds of formula (VII) may be prepared from compounds of formula (VIII):
wherein R3 and Y are as previously defined.
The reaction is generally carried out using about a 20% excess of (X) in the presence of an excess of a tertiary amine such as triethylamine or pyridine to act as scavenger for the acid by-product (HY), optionally in the presence of a catalyst such as 4-dimethylamino-pyridine, in an inert solvent such as dichloromethane at from about 0 to about 25°C for 2-24 hours. For convenience, pyridine may also be used as solvent.
Compounds of formula (I) may be obtained more directly from a compound of formula (XI):
wherein R3, R4 and Y are as previously defined, when such acyl halides are readily accessible, by reaction with (VIII) and subsequent ring-closure of the product as described above. Clearly this alternative synthetic route will only be appropriate when R4 is compatible with the reaction conditions obtaining in both steps.
The aminopyrazole carboxamides of formula (VIII) may be obtained by acid hydrolysis of the corresponding nitriles of formula (IX), whilst the latter, the acyl halides of formulae (X) and (XI), and the intermediates employed for introduction of the various R4
substituents into compounds of formula (II) to afford compounds of formula (I), when neither commercially
available nor subsequently described, can be obtained by conventional synthetic procedures, in accordance with literature precedent, from readily accessible starting materials using appropriate reagents and reaction conditions.
The pharmaceutically acceptable acid addition salts of the compounds of formula (I) which contain a basic centre may also be prepared in a conventional manner. For example a solution of the free base is treated with the appropriate acid, either neat or in a suitable solvent, and the resulting salt isolated either by filtration or by evaporation under vacuum of the reaction solvent. Pharmaceutically acceptable base addition salts can be obtained in an analogous manner by treating a solution of a compound of formula (I) with the appropriate base. Both types of salt may be formed or interconverted using ion-exchange resin techniques.
All of the above reactions are entirely
conventional and the necessary reagents and conditions for their performance can readily be established by reference to standard textbooks and to the Examples and Preparations provided hereafter. Alternatives and variations will also be evident to persons skilled in the art to enable all the compounds defined by formula (I) to be prepared.
The biological activities of the compounds of the present invention were determined by the following test methods.
Phosphodiesterase activity
Compound affinities for cGMP and cAMP PDEs are assessed by determination of their IC50 values (the concentration of inhibitor required for 50% inhibition of enzyme activity). The PDE enzymes are isolated from rabbit platelets and rat kidney, essentially by the method of W.J. Thompson et al.. (Biochem., 1971, 10,
311). The calcium/calmodulin (Ca/CAM)-independent cGMP PDE and the cGMP-inhibited cAMP PDE enzymes are
obtained from rabbit platelets whilst, of the four major PDE enzymes of the rat kidney, the Ca/CAM- dependent cGMP PDE (fraction I) is isolated. Assays are performed using a modification of the "batch" method of W.J. Thompson and M.M. Appleman (Biochem., 1979, 18, 5228). Results from these tests show that the compounds of the present invention are potent and selective inhibitors of Ca/CAM-independent cGMP PDE. Platelet anti-aggregatory activity
This is assessed by the determination of a
compound's ability to inhibit platelet aggregation in vitro induced by platelet activating factor (PAF), and to potentiate the platelet antiaggregatory action in vitro of activators of guanylate cyclase such as nitroprusside and EDRF. Washed platelets are prepared essentially by the method of J.F. Mustard et al.
(Methods in Enzymol., 1989, 169. 3) and aggregation is determined using standard turbidimetric techniques as described by G.V.R. Born, (J. Physiol. (Lond), 1962, 162, 67P).
Antihypertensive activity
This is assessed following intravenous or oral administration of a compound to spontaneously
hypertensive rats. Blood pressure is recorded via a cannula implanted in the carotid artery of either conscious or anaesthetised animals.
For administration to man in the curative or prophylactic treatment of the disorders identified on page 1, oral dosages of the compounds will generally be in the range of from 4-800 mg daily for an average adult patient (70 kg). Thus for a typical adult patient, individual tablets or capsules contain from 2-400 mg of active compound, in a suitable
pharmaceutically acceptable vehicle or carrier, for
administration in single or multiple doses, once or several times per day. Dosages for intravenous, buccal or sublingual administration will typically be within the range of from 1-400 mg per single dose as required. In practice the physician will determine the actual dosing regimen which will be most suitable for an individual patient and it will vary with the age, weight and response of the particular patient. The above dosages are exemplary of the average case but there can be individual instances in which higher or lower dosage ranges may be merited, and such are within the scope of this invention.
For human use, the compounds of the formula (I) can be administered alone, but will generally be administered in admixture with a pharmaceutical carrier selected with regard to the intended route of
administration and standard pharmaceutical practice. For example, they may be administered orally, buccally or sublingually, in the form of tablets containing excipients such as starch or lactose, or in capsules or ovules either alone or in admixture with excipients, or in the form of elixirs or suspensions containing
flavouring or colouring agents. The compounds may also be injected parenterally, for example intravenously, intramuscularly, subcutaneously or intracoronarily.
For parenteral administration, they are best used in the form of a sterile aqueous solution which may
contain other substances, for example salts, or
monosaccharides such as mannitol or glucose, to make the solution isotonic with blood.
Thus the invention provides a pharmaceutical composition comprising a compound of the formula (I), or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable diluent or carrier.
The invention also provides a compound of the formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing
either entity, for use in medicine.
The invention further provides the use of a compound of the formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical
composition containing either entity, for the
manufacture of a medicament for the treatment of stable, unstable and variant (Prinzmetal) angina, hypertension, pulmonary hypertension, congestive heart failure, atherosclerosis, stroke, peripheral vascular disease, conditions of reduced blood vessel patency e.g. post-PTCA, chronic asthma, bronchitis, allergic asthma, allergic rhinitis, glaucoma, or diseases characterised by disorders of gut motility, e.g. IBS.
In a further aspect, the invention provides a method of treating or preventing stable, unstable and variant (Prinzmetal) angina, hypertension, pulmonary hypertension, congestive heart failure,
atherosclerosis, stroke, peripheral vascular disease, conditions of reduced blood vessel patency e.g. post-PTCA, chronic asthma, bronchitis, allergic asthma, allergic rhinitis, glaucoma, or diseases characterised by disorders of gut motility, e.g. IBS, in a mammal (including a human being) which comprises administering to said mammal a therapeutically effective amount of a compound of formula (I), or a pharmaceutically
acceptable salt thereof, or a pharmaceutical
composition containing either entity.
The invention also includes any novel
intermediates of formulae (II), (III), (IV) and (V) disclosed herein.
The syntheses of the compounds of the invention and of the intermediates for use therein are
illustrated by the following Examples and Preparations. The purity of the compounds was routinely monitored by thin layer chromatography (TLC) using Merck Kieselgel 60 F254 plates. 1H-Nuclear magnetic resonance (NMR) spectra were recorded using either a Nicolet QE-300 or
a Bruker AC-300 spectrometer and were in all cases consistent with the proposed structures.
EXAMPLE 1
6-(2-Ethoxyphenyl)-1-n-propyl-1,5-dihydro-4H- pyrazolo[3,4-d]pyrimidin-4-one
A solution of 5-(2-ethoxybenzamido)-1-n-propyl- pyrazole-4-carboxamide (Preparation 2; 0.541 g, 0.0017 mol) and sodium hydroxide (0.10 g, 0.0026 mol) in a mixture of water (5 ml) and ethanol (1 ml) was heated under reflux for 20 hours. The cool reaction solution was extracted with dichloromethane (5 × 30 ml), then the combined extracts dried (Na2SO4) and evaporated under vacuum to give the crude product. Purification by column chromatography (SiO2, 5% MeOH in CH2Cl2) afforded the title compound as a white solid (0.45 g, 89%). Crystallisation of a sample from ethyl acetate-hexane gave colourless needles, m.p. 154-155°C. Found: C,64.45; H,5.97; N,18.89. C16H18N4O2 requires C, 64.41; H,6.08; N, 18.78%.
EXAMPLE 2
6-[2-Ethoxy-5-(4-methyl-1-piperazinylsulphonyl)phenyl]-1-n-propyl-1,5-dihydro-4H-pyrazolo[3,4-d]Pyrimidin-4-one
A solution of N-methylpiperazine (0.79 g, 0.0079 mol) in ethanol (10 ml) was added to a stirred
suspension of 6-(5-chlorosulphonyl-2-ethoxyphenyl)-1-propyl-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (Preparation 3; 0.78 g, 0.00197 mol) in ethanol (40 ml). After 2 hours at room temperature, the solvent was removed by evaporation under vacuum. The residue was partitioned between saturated aqueous sodium bicarbonate solution (20 ml) and dichloromethane (30 ml), the organic layer removed and the aqueous phase extracted with more dichloromethane (3 × 30 ml). The combined organic solutions were dried (Na2SO4) and the solvent removed by evaporation under vacuum. The residue was purified first by column chromatography (Si02, 5% MeOH in CH2Cl2) and then crystallisation from
ethyl acetate to afford the title compound as white crystals (0.35 g, 35%), m.p. 82-84°C. Found: C, 51.66; H,5.72; N,16.32. C21H28N6O4S; 0.5 CH2Cl2 requires C, 51.39; H,5.72; N,16.72%.
EXAMPLE 3
6-[2-Ethoxy-5-(morpholinoacetyl)phenyl]-1-n-propyl-1,5- dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one
Morpholine (0.175 g, 0.002 mol) was added to a stirred suspension of 6-(5-bromoacetyl-2-ethoxyphenyl)- 1-n-propyl-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4- one (Preparation 4; 0.70 g, 0.0017 mol) and anhydrous potassium carbonate (0.461 g, 0.0033 mol) in
acetonitrile (30 ml) and the resulting mixture stirred at room temperature for 3 hours. The solvent was removed by evaporation under vacuum, the residue partitioned between water (20 ml) and dichloromethane (30 ml), the organic phase removed and the aqueous phase extracted with dichloromethane (3 × 30 ml). The combined organic solutions were dried (Na2SO4) and the solvent removed by evaporation under vacuum to give a yellow oil. Purification by column chromatography
(SiO2, 5% MeOH in CH2Cl2), followed by crystallisation from ethyl acetate-hexane, provided the title compound as white crystals (0.62 g, 85%), m.p. 160-162°C.
Found: C,61.96; H,6.29; N,16.32. C22H27N5O4 requires
C,62.10; H,6.40; N,16.46%.
EXAMPLE 4
6-{2-Ethoxy-5-[4-(2-hydroxyethyl)-1-piperazinylacetyl]-phenyl}-1-n-propyl-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one
Prepared by the same method as Example 3 from N-(2-hydroxyethyl)piperazine (0.156 g, 0.0012 mol), 6-(5-bromoacetyl-2-ethoxyphenyl)-1-n-propyl-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (Preparation 4; 0.412 g, 0.001 mol) and anhydrous potassium carbonate (0.272 g,
0.002 mol) in acetonitrile (30 ml). The product was obtained as pale yellow crystals (0.34 g, 74%), m.p. 166-169°C, after crystallisation from ethyl acetate- hexane. Found: C,61.33; H,6.72; N,18.03. C24H32N6O4 requires C,61.52; H,6.88; N,17.94%.
EXAMPLE 5
6-[2-Ethoxy-5-(2,4-dimethyl-1-imidazolylacetyl)phenyl]- 1-n-propyl-1.5-dihydro-4H-pyrazolo[3,4-d)pyrimidin-4- one
Prepared by the same method as Example 3 from 2,4- dimethylimidazole hydrochloride (0.265 g, 0.002 mol), 6-(5-bromoacetyl-2-ethoxyphenyl)-1-n-propyl-1,5- dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (0.412 g, 0.001 mol) and anhydrous potassium carbonate (0.272 g, 0.002 mol) in acetonitrile (30 ml). The product was obtained as a brown powder after crystallisation from ethyl acetate-hexane (0.10 g, 22%), m.p. 166°C (dec). Found C,60.82; H,5.69; N,17.93. C23H26N6O3; 0.3 CH2Cl2 requires C, 60.84; H,5.82; N, 18.27%.
EXAMPLE 6
6-(5-Bromo-2-ethoxyphenyl)-1-n-propyl-1,5-dihydro-4H-pyrazolo[3.4-d]pyrimidin-4-one
A solution of N-bromosuccinimide (1.0 g, 0. 0056 mol) in DMF (10 ml) was added dropwise to a stirred solution of 6-(2-ethoxyphenyl)-1-n-propyl-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (Example 1; 0.84 g, 0.0028 mol) in DMF (10 ml) and the resulting red solution stirred for 20 hours. The solvent was removed by evaporation under vacuum and the residue partitioned between saturated aqueous sodium bicarbonate solution (20 ml) and ethyl acetate (20 ml). The organic phase was removed and the aqueous phase extracted with ethyl acetate (3 × 30 ml). The combined organic solutions were dried and the solvent removed by evaporation under vacuum to give an orange crystalline solid.
Recrystallisation from ethyl acetate-hexane gave the title compound as colourless crystals (0.812 g, 78%), m.p. 172-173°C. Found: C,51.13; H,4.41; N,14.84.
C16H17BrN4O2 requires C,50.94; H,4.54; N,14.85%.
EXAMPLE 7
4-Ethoxy-3-(4-oxo-1-n-propyl-1,5-dihydro-4H-pyrazolo- [3,4-d]pyrimidin-6-yl)benzoic acid
n-Butyllithium (2.5 M solution in hexane, 2.0 ml,
0.005 mol) was added dropwise to a stirred solution of
6-(5-bromo-2-ethoxyphenyl)-1-n-propyl-1,5-dihydro-4H- pyrazolo[3,4-d]pyrimidin-4-one (0.755 g, 0.002 mol) in dry THF (20 ml) at -78°C under a dry nitrogen
atmosphere. The bright yellow solution was stirred for 1 hour at -78°C, then excess crushed solid carbon dioxide was added and the resulting solution was allowed to warm to room temperature. Saturated aqueous ammonium chloride solution (3 ml) was then added and the solvents removed by evaporation under vacuum. The residue was partitioned between saturated aqueous sodium carbonate solution (30 ml) and dichloromethane (30 ml), the organic phase was removed and the aqueous phase extracted with further dichloromethane (3 × 30 ml). The aqueous phase was then acidified to pH 1 with concentrated hydrochloric acid and extracted with ethyl acetate (5 × 40 ml). The combined ethyl acetate extracts were dried (Na2SO4) and the solvent removed by evaporation under vacuum to give a white solid.
Crystallisation from ethyl acetate-methanol gave the title compound as a white powder (0.130 g, 19%), m.p. 277-279°C. Found: C,59.64; H,5.19; N,16.39. C17H18N4O4 requires C,59.64; H,5.23; N,16.37%.
EXAMPLE 8
6-[2-Ethoxy-5-(4-methyl-1-piperazinylcarbonyl)phenyl]-1-n-propyl-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one
Excess oxalyl chloride (3 ml) was added dropwise to a stirred suspension of 4-ethoxy-3-(4-oxo-1-n- propyl-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-6- yl)benzoic acid (Exmple 7; 0.040 g, 0.0001 mol) in a mixture of DMF (1 drop) and dichloromethane (10 ml). After 2 hours at room temperature, the solvent was removed by evaporation under vacuum and the residue dissolved in dichloromethane (10 ml). Excess N-methylpiperazine (0.1 ml) was then added and the resulting mixture stirred for 15 minutes before being evaporated to dryness under vacuum. The residue was dissolved in saturated aqueous sodium bicarbonate solution (10 ml) and the solution extracted with ethyl acetate (6 × 30 ml). The combined extracts were dried (Na2SO4) and the solvent removed by evaporation under vacuum. The resulting solid was purified by column chromatography (SiO2, 5% MeOH in CH2Cl2) to give the title compound as a white powder (0.028 g, 56%), m.p. 124-127°C. Found: C,62.06; H,6.26; N, 19.44. C22H28N6O3 requires C,62.25; H,6.65; N, 19.80%.
EXAMPLE 9
3-Methyl-6-(2-n-propoxyphenyl)-1-n-propyl-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one
The title compound was prepared from 3-methyl-5-(2-n-propoxybenzamido)-1-n-propylpyrazole-4-carboxamide (Preparation 7; 5.456 g, 0.0016 mol) and sodium
hydroxide (3.16 g, 0.079 mol) in a mixture of water (150 ml) and ethanol (30 ml), by the method of Example 1, and was obtained as a white solid (4.863 g, 94%) after column chromatography. A sample crystallised from ethyl acetate-hexane as colourless needles, m.p. 112-114°C. Found: C,66.35; H,6.79; N,17.12. C18H22N4O2 requires C,66.24; H,6.79; N, 17.17%.
EXAMPLE 10
3-Methyl-6-[5-(morpholinosulphonyl)-2-n-propoxyphenyl]- 1-n-propyl-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4- one
The title compound was prepared from morpholine (0.451 g, 0.0052 mol) and 6-(5-chlorosulphonyl-2-n- propoxyphenyl)-3-methyl-1-n-propyl-1,5-dihydro-4H- pyrazolo[3,4-d]pyrimidin-4-one (Preparation 8; 0.55 g, 0.0013 mol), according to the procedure of Example 2, and was obtained as colourless needles (0.403 g, 65%), m.p. 161-163°C, after crystallisation from ethyl acetate-hexane. Found: C,55.68; H,6.16; N,14.85.
C22H29N5O5S requires C,55.56; H,6.15; N,14.73%.
EXAMPLE 11
6-(5-Bromo-2-n-propoxyphenyl)-3-methyl-1-n-propyl-1,5- dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one
The title compound was prepared from N- bromosuccinimide (4.9 g, 0.0276 mol) and 3-methyl-6-(2- n-propoxyphenyl)-1-n-propyl-1,5-dihydro-4H-pyrazolo- [3,4-d]pyrimidin-4-one (Example 9; 3.0 g, 0.0092 mol), following the procedure of Example 6, and was obtained as yellow crystals (1.11 g, 30%), m.p. 157-159°C, after crystallisation from ethyl acetate. Found: C,53.14; H,5.17; N, 13.76. C18H21BrN4O2 requires C,53.34; H,5.22; N,13.82%.
EXAMPLE 12
(E)-3-(3-Methyl-4-oxo-1-n-propyl-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-6-yl)-4-n-propoxycinnamic acid t-butyl ester
To a solution of 6-(5-bromo-2-n-propoxyphenyl)-3-methyl-1-n-propyl-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (Example 11; 2.14 g, 0.0053 mol) and triethylamine (0.81 g, 0.008 mol) in acetonitrile (4 ml), was added palladium(II) acetate (0.06 g, 0.00027 mol), tri-o-tolylphosphine (0.16 g, 0.00053 mol) and t-
butyl acrylate (1.03 g, 0.008 mol). The mixture was heated under reflux for 4 hours, cooled to room
temperature and then partioned between water (30 ml) and dichloromethane (30 ml). The organic phase was removed and the aqueous phase extracted with
dichloromethane (2 × 30 ml). The combined organic solutions were dried (Na2SO4) and the solvent removed by evaporation under vacuum to give a greenish brown solid. Purification by column chromatography (SiO2, CH2Cl2 then 2% MeOH in CH2Cl2) and crystallisation from ethyl acetate-hexane afforded the title compound as white crystals (1.48 g, 58%), m.p. 181-182°C.
Found: C, 66.50; H,6.75; N,12.27. C25H32N4O4 requires
C,66.35; H,7.12; N,12.38%.
EXAMPLE 13
(E)-3-(3-Methyl-4-oxo-1-n-propyl-1,5-dihydro-4H-pyrazolop3,4-d]pyrimidin-6-yl)-4-n-propoxycinnamic acid
2N Aqueous sodium hydroxide solution (8.0 ml, 0.016 mol) was added to a solution of (E)-3-(3-methyl-4-oxo-1-n-propyl-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-6-yl)-4-n-propoxycinnamic acid t-butyl ester (Example 12; 1.8 g, 0.004 mol) in methanol (8 ml) and the mixture heated under reflux for 5 hours. The methanol was removed by evaporation under vacuum and the aqueous solution acidified to pH 1 with 2N
hydrochloric acid. Exhaustive extraction of the product with 10% methanol in ethyl acetate was followed by drying of the combined extracts (Na2SO4) and
evaporation of solvents under vacuum to furnish an off-white solid. Crystallisation from ethyl acetate-methanol afforded the title compound as white crystals (0.18 g, 12%), m.p. 231-232°C. Found: C,63.52; H,5.96; N,14.00. C21H24N4O4 requires C,63.62; H,6.10; N,14.13%.
EXAMPLE 14
N-[(E)-3-(3-Methyl-4-oxo-1-n-propyl-1,5-dihydro-4H- pyrazolo[3,4-d]pyrimidin-6-yl)-4-n-propoxy- cinnamoyl]morpholine
To a stirred solution of (E)-3-(3-methyl-4-oxo-1- n-propyl-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-6-yl)- 4-n-propoxycinnamic acid (Example 13; 1.0 g, 0.0025 mol) and morpholine (0.21 g, 0.0025 mol) in
dichloromethane at 0°C was added, sequentially, N- methylmorpholine (0.5 g, 0.005 mol), 1-hydroxybenzotriazole hydrate (0.383 g, 0.0025 mol) and 1-(3- dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.957 g, 0.005 mol). The reaction mixture was allowed to warm to room temperature, stirred for 20 hours and evaporated under vacuum, then the residue partitioned between water (30 ml) and dichloromethane (30 ml). The organic phase was removed and the aqueous phase
extracted with more dichloromethane (2 × 30 ml); the combined organic solutions were then dried (Na2SO4) and the solvent removed under vacuum to give a white solid. Purification by column chromatography (SiO2, CH2Cl2 then 3% MeOH in CH2Cl2) and crystallisation from ethyl acetate-hexane-methanol afforded the title compound as white crystals (0.74 g, 63%), m.p. 156-157°C. Found: C,64.60; H,6.85; N,15.16. C25H31N5O4 requires C, 64.50; H,6.71; N,15.04%.
EXAMPLE 15
N-{3-[3-(3-Methyl-4-oxo-1-n-propyl-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-6-yl)-4-n-propoxyphenyl]-propanoyl}morpholine
A solution of N-[(E)-3-(3-methyl-4-oxo-1-n-propyl-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-6-yl)-4-n-propoxycinnamoyl]morpholine (0.5 g, 0.0011 mol) in ethanol (30 ml) was stirred with 10% palladium on charcoal catalyst (0.05 g) under a hydrogen pressure of 50 p.s.i. (3.45 bar) at room temperature for 14 hours.
The reaction mixture was filtered and solvent removed by evaporation under vacuum. Trituration of the residue with diethyl ether, followed by crystallisation from ethyl acetate-hexane, afforded the title compound as white crystals (0.37 g, 74%), m.p. 132-133°C.
Found: C,64.39; H,7.26; N, 14.80. C25H33N5O4 requires C,64.22; H,7.11; N, 14.98%.
PREPARATION 1
5-Amino-1-n-propylpyrazole-4-carboxamide
A solution of 5-amino-4-cyano-1-n-propylpyrazole (J. Med. Chem., 1968, 11, 79; 4.0 g, 0.0027 mol) in a mixture of concentrated sulphuric acid (30 ml) and water (3 ml) was heated at 90°C for 1 hour. The cool reaction mixture was poured into ice/water (70 g) and the resulting mixture basified with solid sodium carbonate to pH 8. The aqueous solution thus obtained was extracted with ethyl acetate (5 × 100 ml), the combined extracts dried (Na2SO4) and the solvent removed by evaporation under vacuum to give the title compound as a pale yellow solid (4.25 g, 95%). A sample was obtained as colourless crystals, m.p. 183-185°C, by crystallisation from methanol-diethyl ether. Found: C,50.39; H,6.94; N,33.2l. C7H12N4O requires C,49.99;
H,7.19; N,33.31%.
PREPARATION 2
5-(2-Ethoxybenzamido)-1-n-propylpyrazole-4-carboxamide
2-Ethoxybenzoyl chloride (0.73 g, 0.0039 mol) was added dropwise to a solution of 5-amino-1-n- propylpyrazole-4-carboxamide (0.56 g, 0.0033 mol) in pyridine (10 ml) and the resulting mixture stirred at room temperature for 20 hours under a dry nitrogen atmosphere. The solvent was removed by evaporation under vacuum and the residue partitioned between dichloromethane (30 ml) and saturated aqueous sodium carbonate solution (30 ml). The organic layer was removed and the aqueous layer extracted with more dichloromethane (2 × 30 ml). The combined organic extracts were dried (Na2SO4) and then evaporated under vacuum. The yellow oil thus obtained was purified by column chromatography (SiO2, 5% MeOH in CH2Cl2) to give the product as a white solid (0.78 g, 74%). A sample was obtained as colourless crystals, m.p. 155-157°C, by crystallisation from ethyl acetate-methanol.
Found: C,60.98; H,6.45; N, 17.78. C16H20N4O3 requires C,60.75; H,6.37; N, 17.71%.
PREPARATION 3
6-(5-Chlorosulphonyl-2-ethoxyphenyl)-1-n-propyl-1,5- dihydro-4H-pyrazolo[3.4-dlpyrimidin-4-one
6-(2-Ethoxyphenyl)-1-n-propyl-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (Example 1; 0.5 g, 0.0017 mol) was added portionwise to stirred
chlorosulphonic acid (3 ml) at 0°C and the resulting solution stirred at room temperature for 14 hours. The reaction mixture was then added dropwise to ice/water (20 g) and the aqueous solution thus obtained was extracted with dichloromethane (4 × 30 ml). The combined extracts were dried (Na2SO4) and the solvent evaporated under vacuum to give a white solid;
trituration with diethyl ether (50 ml) gave the title compound (0.67 g, 100%), m.p. 177-180°C, which was used without further purification.
PREPARATION 4
6-(5-Bromoacetyl-2-ethoxyphenyl)-1-n-propyl-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one
Aluminium trichloride (1.34 g, 0.010 mol) was added portionwise to a stirred solution of 6-(2-ethoxyphenyl)-1-n-propyl-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (Example 1; 1.0 g, 0.0034 mol) and bromoacetyl bromide (1.35, 0.0067 mol) in
dichloromethane (30 ml) at 0°C. The reaction solution was allowed to warm to room temperature, stirred for 14 hours, then for a further 2 hours under reflux. The cool reaction mixture was added dropwise to ice/water (50 g) and the resulting mixture stirred for 1 hour. The organic phase was separated and the aqueous phase extracted with dichloromethane (2 × 50 ml); the
combined organic solutions were then washed with brine (10 ml) and dried (Na2SO4). Removal of the solvent by
evaporation under vacuum gave an off-white solid which, when triturated with ether (20 ml) and dried, afforded the product as a white solid (1.29 g, 92%). A sample crystallised from ethyl acetate-hexane as colourless crystals, m.p. 164-166°C. Found: C,51.88; H,4.56;
N,13.13. C18H19BrN4O3 requires C,51.56; H,4.57; N,13.36%.
PREPARATION 5
5-Amino-4-cyano-3-methyl-1-n-propylpyrazole
Sodium methoxide (0.73 g, 0.0135 mol) was added to a suspension of n-propylhydrazine oxalate (1.05 g, 0.0064 mol) in methanol (20 ml) and the mixture stirred for 2 hours at room temperature. (1-Ethoxyethylidene)malononitrile (0.88 g, 0.0064 mol) was then added portionwise over 10 minutes and the resulting mixture heated under reflux for 4 hours. The reaction mixture was allowed to cool and the solvent removed by evaporation under vacuum. Dichloromethane (20 ml) was added to the residue and, after vigorous stirring of the mixture, the suspension was filtered. The filtrate was evaporated under vacuum and the residue purified by column chromatography (SiO2, 2% MeOH in CH2Cl2) to give the title compound as pale brown crystals (0.50 g, 48%). A sample crystallised from ethyl acetate as pale brown needles, m.p. 104-105°C. Found: C,58.82; H,7.30; N,34.13. C8H12N4 requires C,58.52; H,7.37; N,34.12%.
PREPARATION 6
5-Amino-3-methyl-1-n-propylpyrazole-4-carboxamide
By the same method as Preparation 1, the title compound was obtained from 5-amino-4-cyano-3-methyl-1-n-propylpyrazole (2.0 g, 0.012 mol), concentrated sulphuric acid (30 ml) and water (3 ml) as a white solid (2.19 g, 98%). A sample crystallised from
methanol-ethyl acetate as colourless crystals, m.p.
165-166°C. Found: C,53.02; H,7.87; N,30.75. C8H14N4O requires C,52.73; H,7.74; N,30.75%.
PREPARATION 7
3-Methyl-5-(2-n-propoxybenzamido)-1-n-propylpyrazole-4- carboxamide
The title compound was prepared from 2-n-propoxy-benzoyl chloride (5.33 g, 0.027 mol) and 5-amino-3-methyl-1-n-propylpyrazole-4-carboxamide (Preparation 6; 4.07 g, 0.022 mol) in pyridine (100 ml), following the procedure of Preparation 2, and was obtained as a white solid (5.84 g, 76%). A sample was crystallised from ethyl acetate-hexane, m.p. 111-113°C. Found: C,62.83; H,7.09; N,16.26. C18H24N4O3 requires C,62.77; H,7.02;
N,16.27%.
PREPARATION 8
6-(5-Chlorosulphonyl-2-n-propoχyphenyl)-3-methyl-1-n-propyl-1,5-dihydro-4H-pyrazolo[3-4-d]pyrimidin-4-one
The title compound was prepared from 3-methyl-6- (2-n-propoxyphenyl)-1-n-propyl-1,5-dihydro-4H-pyrazolo-[3,4-d]pyrimidin-4-one (Example 9; 0.5 g, 0.0017 mol) and chlorosulphonic acid (3 ml), by the same procedure as Preparation 3 , and was obtained as a white powder (0.587 g, 90%), m.p. 148-150°C. Found: C,50.88;
H,4.67; N,13.30. C18H21ClN4O4S requires C,50.88; H,4.98; N,13.19%.
Biological activity
The following Table illustrates the in vitro activities for a range of the compounds of the invention.
Safety profile
Example 3 has been tested at therapeutic doses of up to 1 mg/Kg i.v. in rabbit with no signs of adverse acute toxicity being observed.
Claims
A compound of formula :
wherein R1 is C1-C6 alkyl;
R2 is H, methyl or ethyl;
R3 is C2-C4 alkyl;
R4 is C1-C4 alkyl optionally substituted with NR5R6, CN, CONR5R6 or CO2R7; C2-C4 alkenyl optionally substituted with CN, CONR5R6 or CO2R7; C2-C4 alkanoyl optionally substituted with NR5R6; SO2NR5R6; CONR5R6; CO2R7; or halo; R5 and R6 are each independently H or C1-C4 alkyl, or together with the nitrogen atom to which they are attached form a pyrrolidino, piperidino, morpholino, 4-(NR8)-1-piperazinyl or 1-imidazolyl group wherein said group is optionally substituted by one or two C1-C4 alkyl groups;
R7 is H or C1-C4 alkyl;
and R8 is H, C1-C3 alkyl or hydroxy C2-C3 alkyl.
2. A compound as claimed in claim 1 wherein R1 is n-propyl; R2 is H or methyl; R3 is ethyl or n-propyl; R4 is ethyl substituted with CONR5R6 or CO2R7; vinyl substituted with CONR5R6 or CO2R7; acetyl substituted with NR5R6; SO2NR5R6; CONR5R6; CO2R7; or bromo; R5 and R6 together with the nitrogen atom to which they are attached form a morpholino, 4-(NR8)-1-piperazinyl or 2,4-dimethyl-1-imidazolyl group; R7 is H or t-butyl; and R8 is methyl or 2-hydroxyethyl.
3. A compound as claimed in claim 2 wherein the said compound is selected from:
6-(5-bromo-2-n-propoxyphenyl)-3-methyl-1-n-propyl- 1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one;
3-methyl-6-(5-morpholinosulphonyl-2-n- propoxyphenyl)-1-n-propyl-1,5-dihydro-4H-pyrazolo[3,4- d]pyrimidin-4-one;
6-[5-(2-carboxyvinyl)-2-n-propoxyphenyl]-3-methyl- 1-n-propyl-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4- one;
6-[5-(2-t-butoxycarbonylvinyl)-2-n-propoxyphenyl]- 3-methyl-1-n-propyl-1,5-dihydro-4H-pyrazolo[3,4- d]pyrimidin-4-one;
3-methyl-6-[5-(2-morpholinocarbonylvinyl)-2-n- propoxyphenyl]-1-n-propyl-1,5-dihydro-4H-pyrazolo[3,4- d]pyrimidin-4-one;
and 3-methyl-6-[5-(2-morpholinocarbonylethyl)-2-n- propoxyphenyl]-1-n-propyl-1,5-dihydro-4H-pyrazolo[3,4- d]pyrimidin-4-one;
and pharmaceutically acceptable salts thereof.
4. A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 3, together with a pharmaceutically acceptable diluent or carrier.
5. A compound of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical
composition containing either entity, as claimed in any one of claims 1 to 4, for use in medicine.
6. The use of a compound of formula (I), or a
pharmaceutically acceptable salt thereof, or a
pharmaceutical composition containing either entity, as claimed in any one of claims 1 to 4, for the
manufacture of a medicament for the treatment of stable, unstable and variant (Prinzmetal) angina, hypertension, pulmonary hypertension, congestive heart failure, atherosclerosis, stroke, peripheral vascular disease, conditions of reduced blood vessel patency, chronic asthma, bronchitis, allergic asthma, allergic rhinitis, glaucoma or diseases characterised by
disorders of gut motility.
7. A method of treating or preventing stable,
unstable and variant (Prinzmetal) angina, hypertension, pulmonary hypertension, congestive heart failure, atherosclerosis, stroke, peripheral vascular disease, condtions of reduced blood vessel patency, chronic asthma, bronchitis, allergic asthma, allergic rhinitis, glaucoma or diseases characterised by disorders of gut motility, in a mammal (including a human being), which comprises administering to said mammal an effective amount of a compound of formula (I), or a
pharmaceutically acceptable salt thereof, or a
pharmaceutical composition containing either entity, as claimed in any one of claims 1 to 4.
8. A process for the preparation of a compound of formula:
or a pharmaceutically acceptable salt thereof, wherein R1 is C1-C6 alkyl;
R2 is H, methyl or ethyl;
R3 is C2-C4 alkyl;
R4 is C1-C4 alkyl optionally substituted with NR5R6, CN, CONR5R6 or CO2R7; C2-C4 alkenyl optionally substituted with CN, CONR5R6 or CO2R7; C2-C4 alkanoyl optionally substituted with NR5R6; SO2NR5R6; CONR5R6; CO2R7; or halo; R5 and R6 are each independently H or C1-C4 alkyl, or together with the nitrogen atom to which they are attached form a pyrrolidino, piperidino, morpholino, 4-(NR8)-1-piperazinyl or 1-imidazolyl group wherein said group is optionally substituted by one or two C1-C4 alkyl groups;
R7 is H or C1-C4 alkyl;
and R8 is H, C1-C3 alkyl or hydroxy C2-C3 alkyl; which comprises reacting a compound of formula: wherein R1, R2 and R3 are as previously defined in this claim, for a compound of formula (I) when R4 is
(A) C2-C4 alkanoyl , with an acyl halide of formula (C1-C3 alkyl) COY wherein Y is halo, in the presence of a Lewis acid;
(B) C2-C4 alkanoyl substituted with NR5R6 wherein R5 and R6 are as previously defined in this claim, with a haloacyl halide of formula X(C1-C3 alkylene)COY wherein X is halo and Y is as previously defined in this claim, in the presence of a Lewis acid, followed by reaction of the resulting haloketone either with an amine of formula R5R6NH, or with a protected amine of formula R5NHP, R6NHP or P'2NH wherein P and P' are suitable amine protecting groups followed by removal of P or P';
(C) halo wherein halo is fluoro, chloro, bromo or iodo. under aromatic nitration conditions, followed by reduction of the resulting nitro compound to the corresponding primary amine, and subjection of the said amine to a conventional diazotisation-halogenation sequence; (P. C1-C4 alkyl optionally substituted with NR5R6, CN, CONR5R6 or CO2R7 wherein R5, R6 and R7 are as previously defined in this claim, or bromo,
(i) under chloromethylation conditions, followed by subjection of the resulting chloromethyl intermediate to, respectively
(a) reduction, or
(b) reaction with an amine of formula R5R6NH, or
(c) reaction with an alkali metal cyanide and
optionally converting the resulting nitrile to the corresponding amide, acid or ester; or
(ii) under aromatic bromination conditions, followed by subjection of the resulting bromo derivative to, respectively,
(a) lithium-bromine exchange, followed by reaction of the aryllithium derivative with ethylene oxide to give the 2-hydroxyethyl derivative, or
(b) reaction with allyl alcohol, followed by catalytic hydrogenation of the alkene to give the 3-hydroxypropyl derivative, or
(c) reaction of 3-buten-1-ol, followed by catalytic hydrogenation of the alkene to give the 4-hydroxybutyl derivative,
and conversion of any of the foregoing alcohols to the corresponding alkane, amine or nitrile by activation of their respective hydroxy groups to give the
intermediate chloride, bromide, iodide or mesylate followed by reduction, or reaction with an amine of formula R5R6NH, or reaction with an alkali metal
cyanide, respectively, and further optional conversion of the said nitrile to the corresponding amide, acid or ester;
(E) C2-C4 alkenyl 2-substituted with CN, CONR5R6 or CO2R7, or C2-C4 alkyl 2-substituted with CN, CONR5R6, CO2R7 or CH2NH2, wherein R5, R6 and R7 are as previously
defined in this claim, via the bromo derivative of (D) (ii) above, with the appropriate α,β-unsaturated nitrile, amide or ester respectively, optionally followed by hydrolysis of any resulting ester, reduction of the resulting alkenyl group and, in the case of the nitrile, further or concomitant reduction of the nitrile group to the corresponding primary amine;
(F) C2-C4 alkenyl, or C2-C4 alkyl, each optionally substituted with CN, CONR5R6 or CO2R7 wherein R5, R6 and R7 are as previously defined in this claim, via the bromo derivative of (D) (ii) above, with a lithium-bromine exchange reagent, followed by
subjection of the aryllithium derivative to
formylation, and reaction of the resulting aldehyde with the appropriate optionally CN-, CONR5R6- or CO2R7-substituted C1-C3 alkyl phosphonium salt or phosphonate, optionally followed by hydrolysis of any resulting ester and reduction of the resulting alkenyl group;
(G) CONR5R6 or CO2R7 wherein R5, R6 and R7 are as
previously defined in this claim, via the bromo derivative of (D) (ii) above, with a lithium-bromine exchange reagent, followed by reaction of the aryllithium derivative with carbon dioxide, and conversion of a suitably activated form of the
resulting carboxylic acid to an amide or ester
derivative by reaction with an amine of formula R5R6NH or alcohol of formula R7OH respectively; (H) SO2NR5R6 wherein R5 and R6 are as previously defined in this claim, with a halosulphonation reagent, followed by reaction of the resulting sulphonyl halide with an amine of formula R5R6NH; followed in each case, by optional isolation as, or formation of, a pharmaceutically acceptable salt of the product.
9. A process for the preparation of a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3 and R4 are as previously defined in claim 8, which comprises reacting a compound of formula:
wherein Y is chloro or bromo, and R3 and R4 are as previously defined in claim 8, with an aminopyrazole of formula:
10. A process as claimed in claim 8 wherein in (A). Y is chloro or bromo, and the Lewis acid is aluminium chloride or aluminium bromide; in (B). X and Y are chloro or bromo, P is benzyl and is removed by catalytic hydrogenation, and P' is t- butoxycarbonyl and is removed using hydrogen chloride; in (C). the nitration is achieved using concentrated nitric acid in combination with concentrated sulphuric acid, and the nitro compound is reduced by catalytic hydrogenation; in (D),
(i) the chloromethylation is carried out using
paraformaldehyde and concentrated hydrochloric acid, and
(a) the reduction is effected by palladium-catalysed hydrogenation,
(b) the reaction with R5R6NH is carried out using an excess of said amine,
(c) the alkali metal cyanide is sodium cyanide or potassium cyanide;
(ii) the aromatic bromination is carried out using N-bromosuccinimide, and
(a) the lithium-bromine excchange is effected using n-butyl1ithium,
(b) the reaction with allyl alcohol is effected under Heck reaction conditions. (c) the reaction with 3-buten-1-ol is effected under Heck reaction conditions; in (E), the reaction with the appropriate α,β- unsaturated nitrile, amide or ester respectively is effected under Heck reaction conditions using tri-o- tolylphosphine, palladium(II) acetate and
triethylamine, the optional hydrolysis of the ester is achieved using aqueous sodium hydroxide solution in methanol, the optional reduction of the alkenyl group is effected by palladium-catalysed hydrogenation, and the optional further or concomitant reduction of the nitrile group is carried out using Raney nickel in glacial acetic acid; in (F), the lithium-bromine exchange is effected using n-butyllithium, the formylation reagent is
dimethylformamide, and the alkene reduction is achieved by catalytic hydrogenation; in (G). the lithium-bromine exchange is effected using n-butyllithium, and the carboxylic acid is activated using a carbodiimide in combination with 1-hydroxybenzotriazole; in (H), the halosulphonation reagent is chlorosulphonic acid, and the reaction with R5R6NH is carried out using an excess of said amine.
11. A process as claimed in any one of claims 8 to 10 wherein R1 is n-propyl; R2 is H or methyl; R3 is ethyl or n-propyl; R4 is ethyl substituted with CONR5R6 or CO2R7; vinyl substituted with CONR5R6 or CO2R7; acetyl substituted with NR5R5; SO2NR5R6; CONR5R6; CO2R7; or bromo; R5 and R6 together with the nitrogen atom to which they are attached form a morpholino, 4-(NR8)-1-piperazinyl or 2,4-dimethyl-1-imidazolyl group; R7 is H or t-butyl; and R8 is methyl or 2-hydroxyethyl.
12. A process as claimed in claim 11 wherein the said compound of formula (I) produced is selected from:
6-(5-bromo-2-n-propoxyphenyl)-3-methyl-1-n-propyl- 1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one;
3-methyl-6-(5-morpholinosulphonyl-2-n-propoxyphenyl)-1-n-propyl-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one;
6-[5-(2-carboxyvinyl)-2-n-propoxyphenyl]-3-methyl-1-n-propyl-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one;
6-[5-(2-t-butoxycarbonylvinyl)-2-n-propoxyphenyl]-3-methyl-1-n-propyl-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one;
3-methyl-6-[5-(2-morpholinocarbonylvinyl)-2-n-propoxyphenyl]-1-n-propyl-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one;
and 3-methyl-6-[5-(2-morpholinocarbonylethyl)-2-n-propoxyphenyl]-1-n-propyl-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one;
and pharmaceutically acceptable salts thereof.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB919121028A GB9121028D0 (en) | 1991-10-03 | 1991-10-03 | Therapeutic agents |
GB9121028.6 | 1991-10-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1993007149A1 true WO1993007149A1 (en) | 1993-04-15 |
Family
ID=10702367
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1992/002237 WO1993007149A1 (en) | 1991-10-03 | 1992-09-24 | Pyrazolopyrimidinone antianginal agents |
Country Status (3)
Country | Link |
---|---|
GB (1) | GB9121028D0 (en) |
PT (1) | PT100915A (en) |
WO (1) | WO1993007149A1 (en) |
Cited By (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0636626A1 (en) * | 1993-07-20 | 1995-02-01 | Laboratoires Glaxo Sa | Pyrazolopyrimidine Derivatives |
WO1996016657A1 (en) * | 1994-11-26 | 1996-06-06 | Pfizer Limited | Bicyclic heterocyclic compounds for the treatment of impotence |
WO1996028448A1 (en) * | 1995-03-10 | 1996-09-19 | Sanofi Winthrop, Inc. | 6-ARYL PYRAZOLO[3,4-d]PYRIMIDIN-4-ONES AND COMPOSITIONS AND METHODS OF USE THEREOF |
US5696159A (en) * | 1994-08-03 | 1997-12-09 | Cell Pathways, Inc. | Lactone compounds for treating patients with precancerous lesions |
EP0813527A1 (en) * | 1995-03-10 | 1997-12-29 | Sanofi Pharmaceuticals, Inc. | 6-SUBSTITUTED PYRAZOLO 3,4-d] PYRIMIDIN-4-ONES AND COMPOSITIONS AND METHODS OF USE THEREOF |
EP0813410A1 (en) * | 1995-03-10 | 1997-12-29 | Sanofi Winthrop, Inc. | SUBSTITUTED N-ARYLMETHYL AND HETEROCYCLYLMETHYL-1H-PYRAZOLO 3,4-b]QUINOLIN-4-AMINES AND COMPOSITIONS AND METHODS OF USE THEREOF |
US5776962A (en) * | 1994-08-03 | 1998-07-07 | Cell Pathways, Inc. | Lactone compounds for treating patient with precancerous lesions |
US5852035A (en) * | 1997-12-12 | 1998-12-22 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure to substituted N- arylmethyl and heterocyclmethyl-1H-pyrazolo (3,4-B) quinolin-4-amines |
US5874440A (en) * | 1995-06-07 | 1999-02-23 | Cell Pathways, Inc. | Method of treating a patient having precancerous lesions with phenyl pyrimidinone derivatives |
WO1999024433A1 (en) * | 1997-11-12 | 1999-05-20 | Bayer Aktiengesellschaft | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors |
US5942520A (en) * | 1998-01-27 | 1999-08-24 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells by exposure to substituted N-cycloalkylmethyl-1-H-pyrazolo (3,4-B) quinolone-4 amines |
US5990117A (en) * | 1998-04-15 | 1999-11-23 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure to quinazoline derivatives |
US6008226A (en) * | 1995-03-10 | 1999-12-28 | Sanofi-Synthelabo | Substituted N-arylmethyl and heterocylylmethyl-1H-pyrazolo[3,4-b]quinolin-4-amines and compositions and methods of use thereof |
US6020379A (en) * | 1999-02-19 | 2000-02-01 | Cell Pathways, Inc. | Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia |
US6034099A (en) * | 1998-11-24 | 2000-03-07 | Cell Pathways, Inc. | Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones |
US6046199A (en) * | 1998-01-14 | 2000-04-04 | Cell Pathways, Inc. | Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B]indole derivatives |
US6046206A (en) * | 1995-06-07 | 2000-04-04 | Cell Pathways, Inc. | Method of treating a patient having a precancerous lesions with amide quinazoline derivatives |
US6046216A (en) * | 1995-06-07 | 2000-04-04 | Cell Pathways, Inc. | Method of treating a patient having precancerous lesions with phenyl pyridinone derivatives |
EP0995751A2 (en) * | 1998-10-23 | 2000-04-26 | Pfizer Inc. | Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction |
US6060477A (en) * | 1995-06-07 | 2000-05-09 | Cell Pathways, Inc. | Method of treating a patient having precancerous lesions with phenyl cycloamino pyrimidinone derivatives |
US6077842A (en) * | 1998-11-24 | 2000-06-20 | Cell Pathways, Inc. | Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives |
US6124303A (en) * | 1998-09-11 | 2000-09-26 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure to 9-substituted 2-(2-N-aloxyphenyl) purin-6-ones |
US6130053A (en) * | 1999-08-03 | 2000-10-10 | Cell Pathways, Inc. | Method for selecting compounds for inhibition of neoplastic lesions |
US6133271A (en) * | 1998-11-19 | 2000-10-17 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives |
US6156528A (en) * | 1997-05-30 | 2000-12-05 | Cell Pathways, Inc | Methods for using a phosphodiesterase in pharmaceutical screening to identify compounds for treatment of neoplasia |
US6174884B1 (en) | 1997-03-11 | 2001-01-16 | Bayer Aktiengesellschaft | 1,5-dihydro-pyrazolo[34-D]-pyrimidinone derivatives |
US6177471B1 (en) | 1999-01-29 | 2001-01-23 | Cell Pathways, Inc. | Method for treating patients with acne by administering a CGMP-specific PDE inhibitor |
US6180629B1 (en) | 1998-08-14 | 2001-01-30 | Cell Pathways, Inc. | [4,5]-Fused-1,3-disubstituted-1,2-diazine-6-one derivatives with nitrogen containing substitutents in position one for the treatment of neoplasia |
US6187779B1 (en) | 1998-11-20 | 2001-02-13 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives |
US6200980B1 (en) | 1995-06-07 | 2001-03-13 | Cell Pathways, Inc. | Method of treating a patient having precancerous lesions with phenyl purinone derivatives |
US6200771B1 (en) | 1998-10-15 | 2001-03-13 | Cell Pathways, Inc. | Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia |
EP1085871A1 (en) * | 1998-06-08 | 2001-03-28 | Bristol-Myers Squibb Company | QUINAZOLINONE INHIBITORS OF cGMP PHOSPHODIESTERASE |
WO2001026659A1 (en) * | 1999-10-12 | 2001-04-19 | Lareida Juerg | Medicament for treatment of neuropathies |
US6225315B1 (en) | 1998-11-30 | 2001-05-01 | Pfizer Inc | Method of treating nitrate-induced tolerance |
US6232312B1 (en) | 1995-06-07 | 2001-05-15 | Cell Pathways, Inc. | Method for treating patient having precancerous lesions with a combination of pyrimidopyrimidine derivatives and esters and amides of substituted indenyl acetic acides |
US6235742B1 (en) | 1997-10-24 | 2001-05-22 | Pfizer Inc. | 5-substituted pyrazolo[4,3-D]pyrimidin-7-ones |
US6251904B1 (en) | 1998-04-20 | 2001-06-26 | Pfizer Inc. | Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction |
EP1113796A1 (en) * | 1998-09-16 | 2001-07-11 | Bristol-Myers Squibb Company | FUSED PYRIDINE INHIBITORS OF cGMP PHOSPHODIESTERASE |
US6262059B1 (en) | 1995-06-07 | 2001-07-17 | Cell Pathways, Inc. | Method of treating a patient having precancerous lesions with quinazoline derivatives |
US6268372B1 (en) | 1998-09-11 | 2001-07-31 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones |
US6300335B1 (en) | 1994-11-26 | 2001-10-09 | Pfizer Inc. | 4-aminoquinazoline derivative cGMP-PDE inhibitors for the treatment of erectile dysfunction |
US6331543B1 (en) | 1996-11-01 | 2001-12-18 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use |
US6333330B1 (en) | 1998-10-23 | 2001-12-25 | Pfizer Inc. | Pyrazolopyrimidinone CGMP PDE5 inhibitors for the treatment of sexual dysfunction |
US6369092B1 (en) | 1998-11-23 | 2002-04-09 | Cell Pathways, Inc. | Method for treating neoplasia by exposure to substituted benzimidazole derivatives |
US6486155B1 (en) | 1998-11-24 | 2002-11-26 | Cell Pathways Inc | Method of inhibiting neoplastic cells with isoquinoline derivatives |
US6500610B1 (en) | 1997-05-30 | 2002-12-31 | Cell Pathways, Inc | Methods for identifying compounds for inhibiting of neoplastic lesions, and pharmaceutical compositions containing such compounds |
US6548508B2 (en) | 2000-10-20 | 2003-04-15 | Pfizer, Inc. | Use of PDE V inhibitors for improved fecundity in mammals |
US6555547B1 (en) | 2000-02-28 | 2003-04-29 | Cell Pathways, Inc. | Method for treating a patient with neoplasia by treatment with a vinca alkaloid derivative |
US6569638B1 (en) | 2000-03-03 | 2003-05-27 | Cell Pathways, Inc | Method for screening compounds for the treatment of neoplasia |
WO2003053923A2 (en) | 2001-12-20 | 2003-07-03 | Applied Research Systems Ars Holding N.V. | Pyrrolidine derivatives as prostaglandin modulators |
WO2003064402A1 (en) | 2002-01-31 | 2003-08-07 | Pfizer Limited | Treatment of male sexual dysfunction |
EP1365806A2 (en) * | 2000-04-19 | 2003-12-03 | Johns Hopkins University | Use of no acttivators for treatment and prevention of gastrointestinal disorders |
US6670366B1 (en) | 1998-10-23 | 2003-12-30 | Pfizer Inc | Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction |
US6677335B1 (en) | 1999-10-11 | 2004-01-13 | Pfizer Inc | Pharmaceutically active compounds |
US6723719B1 (en) | 1997-04-25 | 2004-04-20 | Pfizer Inc | Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3′,5′—monophosphate phosphodiesterase (cGMP PDE5) for the treatment of sexual dysfunction |
US6756373B1 (en) | 1999-10-11 | 2004-06-29 | Pfizer Inc. | Pharmaceutically active compounds |
JP2004521924A (en) * | 2001-03-05 | 2004-07-22 | イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー | Heterocyclic diamide invertebrate pest control agent |
US6797701B2 (en) | 1998-11-19 | 2004-09-28 | Pfizer Inc. | Antiparasitic formulations |
US6867320B2 (en) | 2002-02-21 | 2005-03-15 | Asahi Kasei Pharma Corporation | Substituted phenylalkanoic acid derivatives and use thereof |
US6911456B2 (en) | 1996-02-28 | 2005-06-28 | Pfizer Inc | Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions |
US6914160B1 (en) | 2002-08-28 | 2005-07-05 | Pfizer Inc | Oxytocin inhibitors |
US6962940B2 (en) | 2002-03-20 | 2005-11-08 | Celgene Corporation | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
US7094782B1 (en) | 1996-07-24 | 2006-08-22 | Bristol-Myers Squibb Company | Azolo triazines and pyrimidines |
US7115647B2 (en) | 1998-01-14 | 2006-10-03 | Osi Pharmaceuticals, Inc. | Method of inhibiting neoplastic cells with indole derivatives |
US7208516B2 (en) | 2002-03-20 | 2007-04-24 | Celgene Corporation | Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
US7235625B2 (en) | 1999-06-29 | 2007-06-26 | Palatin Technologies, Inc. | Multiple agent therapy for sexual dysfunction |
US7262192B2 (en) | 2003-04-29 | 2007-08-28 | Pfizer Inc. | Substituted pyrazolo[4,3-d]pyrimidines and their use as PDE-5 inhibitors |
US7276529B2 (en) | 2002-03-20 | 2007-10-02 | Celgene Corporation | Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
US7291640B2 (en) | 2003-09-22 | 2007-11-06 | Pfizer Inc. | Substituted triazole derivatives as oxytocin antagonists |
US7323462B2 (en) | 2002-12-10 | 2008-01-29 | Pfizer Inc. | Morpholine dopamine agonists |
US7470807B2 (en) | 2003-08-14 | 2008-12-30 | Asahi Kasei Pharma Corporation | Substituted arylalkanoic acid derivatives and use thereof |
US7560564B2 (en) | 2001-03-05 | 2009-07-14 | E.I. Du Pont De Nemours And Company | Heterocyclic diamide invertebrate pest control agents |
US7569572B2 (en) | 2004-04-07 | 2009-08-04 | Pfizer Inc | Pyrazolo[4,3-D]pyrimidines |
US7572799B2 (en) | 2003-11-24 | 2009-08-11 | Pfizer Inc | Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors |
EP2196201A2 (en) | 2002-12-13 | 2010-06-16 | Warner-Lambert Company LLC | Combination of an alpha-2-delta ligand with a pdev inhibitor or a muscarinic antagonist to treat lower urinary tract symptoms |
US7893101B2 (en) | 2002-03-20 | 2011-02-22 | Celgene Corporation | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
US8227475B2 (en) | 2005-05-12 | 2012-07-24 | Pfizer Inc. | Anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide |
US8273876B2 (en) | 2002-07-16 | 2012-09-25 | Bayer Intellectual Property Gmbh | Medicaments containing vardenafil hydrochloride trihydrate |
WO2013067309A1 (en) | 2011-11-04 | 2013-05-10 | Xion Pharmaceutical Corporation | Methods and compositions for oral administration of melanocortin receptor agonist compounds |
US8697875B2 (en) | 2008-12-23 | 2014-04-15 | The Trustees Of Columbia University In The City Of New York | Phosphodiesterase inhibitors and uses thereof |
US10300042B2 (en) | 2014-06-23 | 2019-05-28 | Celgene Corporation | Apremilast for the treatment of a liver disease or a liver function abnormality |
US10981916B2 (en) | 2016-12-28 | 2021-04-20 | Dart Neuroscience, Llc | Substituted pyrazolopyrimidinone compounds as PDE2 inhibitors |
US11434247B1 (en) | 2017-11-27 | 2022-09-06 | Dart Neuroscience Llc | Substituted furanopyrimidine compounds as PDE1 inhibitors |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0201188A2 (en) * | 1985-04-05 | 1986-12-17 | Warner-Lambert Company | 5-Substituted pyrazolo[4,3-d] pyrimidine-7-ones, process for preparing the compounds and pharmaceutical compositions comprising the compounds |
EP0349239A2 (en) * | 1988-07-01 | 1990-01-03 | Smith Kline & French Laboratories Limited | Condensed pyrimidine derivatives, process and intermediates for their preparation and pharmaceutical compositions containing them |
EP0463756A1 (en) * | 1990-06-20 | 1992-01-02 | Pfizer Limited | Pyrazolopyrimidinone antianginal agents |
-
1991
- 1991-10-03 GB GB919121028A patent/GB9121028D0/en active Pending
-
1992
- 1992-09-24 WO PCT/EP1992/002237 patent/WO1993007149A1/en active Application Filing
- 1992-09-30 PT PT10091592A patent/PT100915A/en not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0201188A2 (en) * | 1985-04-05 | 1986-12-17 | Warner-Lambert Company | 5-Substituted pyrazolo[4,3-d] pyrimidine-7-ones, process for preparing the compounds and pharmaceutical compositions comprising the compounds |
EP0349239A2 (en) * | 1988-07-01 | 1990-01-03 | Smith Kline & French Laboratories Limited | Condensed pyrimidine derivatives, process and intermediates for their preparation and pharmaceutical compositions containing them |
EP0463756A1 (en) * | 1990-06-20 | 1992-01-02 | Pfizer Limited | Pyrazolopyrimidinone antianginal agents |
Cited By (150)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0636626A1 (en) * | 1993-07-20 | 1995-02-01 | Laboratoires Glaxo Sa | Pyrazolopyrimidine Derivatives |
US5696159A (en) * | 1994-08-03 | 1997-12-09 | Cell Pathways, Inc. | Lactone compounds for treating patients with precancerous lesions |
US5776962A (en) * | 1994-08-03 | 1998-07-07 | Cell Pathways, Inc. | Lactone compounds for treating patient with precancerous lesions |
US6656945B2 (en) | 1994-11-26 | 2003-12-02 | Pfizer Inc | 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-one cGMP-PDE inhibitors for the treatment of erectile dysfunction |
WO1996016657A1 (en) * | 1994-11-26 | 1996-06-06 | Pfizer Limited | Bicyclic heterocyclic compounds for the treatment of impotence |
US6300335B1 (en) | 1994-11-26 | 2001-10-09 | Pfizer Inc. | 4-aminoquinazoline derivative cGMP-PDE inhibitors for the treatment of erectile dysfunction |
US6100270A (en) * | 1994-11-26 | 2000-08-08 | Pfizer Inc. | Bicyclic heterocyclic compounds for the treatment of impotence |
US6534511B1 (en) | 1994-11-26 | 2003-03-18 | Pfizer Inc. | Bicyclic heterocyclic compounds for the treatment of impotence |
US6008226A (en) * | 1995-03-10 | 1999-12-28 | Sanofi-Synthelabo | Substituted N-arylmethyl and heterocylylmethyl-1H-pyrazolo[3,4-b]quinolin-4-amines and compositions and methods of use thereof |
US5736548A (en) * | 1995-03-10 | 1998-04-07 | Sanofi | 6-aryl pyrazolo 3,4-D! pyrimidin-4-ones and compositions and method of use thereof |
WO1996028448A1 (en) * | 1995-03-10 | 1996-09-19 | Sanofi Winthrop, Inc. | 6-ARYL PYRAZOLO[3,4-d]PYRIMIDIN-4-ONES AND COMPOSITIONS AND METHODS OF USE THEREOF |
EP0813527A1 (en) * | 1995-03-10 | 1997-12-29 | Sanofi Pharmaceuticals, Inc. | 6-SUBSTITUTED PYRAZOLO 3,4-d] PYRIMIDIN-4-ONES AND COMPOSITIONS AND METHODS OF USE THEREOF |
EP0813410A4 (en) * | 1995-03-10 | 1998-08-19 | Sanofi Winthrop Inc | SUBSTITUTED N-ARYLMETHYL AND HETEROCYCLYLMETHYL-1H-PYRAZOLO 3,4-b]QUINOLIN-4-AMINES AND COMPOSITIONS AND METHODS OF USE THEREOF |
AU708809B2 (en) * | 1995-03-10 | 1999-08-12 | Sanofi Pharmaceuticals, Inc. | 6-aryl pyrazolo{3,4-d}pyrimidin-4-ones and compositions and methods of use thereof |
EP0813527A4 (en) * | 1995-03-10 | 1998-09-09 | Sanofi Winthrop Inc | 6-SUBSTITUTED PYRAZOLO 3,4-d] PYRIMIDIN-4-ONES AND COMPOSITIONS AND METHODS OF USE THEREOF |
US5958929A (en) * | 1995-03-10 | 1999-09-28 | Sanofi | 6-aryl pyrazolo 3,4-d! pyrimidin-4-ones and compositions and methods of use thereof |
US5977118A (en) * | 1995-03-10 | 1999-11-02 | Sanofi | 6-substituted pyrazolo[3,4-d]pyrimidin-4-ones and compositions and methods of use thereof |
EP0813410A1 (en) * | 1995-03-10 | 1997-12-29 | Sanofi Winthrop, Inc. | SUBSTITUTED N-ARYLMETHYL AND HETEROCYCLYLMETHYL-1H-PYRAZOLO 3,4-b]QUINOLIN-4-AMINES AND COMPOSITIONS AND METHODS OF USE THEREOF |
US6046216A (en) * | 1995-06-07 | 2000-04-04 | Cell Pathways, Inc. | Method of treating a patient having precancerous lesions with phenyl pyridinone derivatives |
US6060477A (en) * | 1995-06-07 | 2000-05-09 | Cell Pathways, Inc. | Method of treating a patient having precancerous lesions with phenyl cycloamino pyrimidinone derivatives |
US6200980B1 (en) | 1995-06-07 | 2001-03-13 | Cell Pathways, Inc. | Method of treating a patient having precancerous lesions with phenyl purinone derivatives |
US6232312B1 (en) | 1995-06-07 | 2001-05-15 | Cell Pathways, Inc. | Method for treating patient having precancerous lesions with a combination of pyrimidopyrimidine derivatives and esters and amides of substituted indenyl acetic acides |
US6046206A (en) * | 1995-06-07 | 2000-04-04 | Cell Pathways, Inc. | Method of treating a patient having a precancerous lesions with amide quinazoline derivatives |
US6262059B1 (en) | 1995-06-07 | 2001-07-17 | Cell Pathways, Inc. | Method of treating a patient having precancerous lesions with quinazoline derivatives |
US5874440A (en) * | 1995-06-07 | 1999-02-23 | Cell Pathways, Inc. | Method of treating a patient having precancerous lesions with phenyl pyrimidinone derivatives |
US6911456B2 (en) | 1996-02-28 | 2005-06-28 | Pfizer Inc | Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions |
US7678793B2 (en) | 1996-07-24 | 2010-03-16 | Bristol-Myers Squibb Pharma Company | Azolo triazines and pyrimidines |
US7094782B1 (en) | 1996-07-24 | 2006-08-22 | Bristol-Myers Squibb Company | Azolo triazines and pyrimidines |
US6331543B1 (en) | 1996-11-01 | 2001-12-18 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use |
US6462044B2 (en) | 1996-11-01 | 2002-10-08 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use |
US6930113B2 (en) | 1996-11-01 | 2005-08-16 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use |
US6174884B1 (en) | 1997-03-11 | 2001-01-16 | Bayer Aktiengesellschaft | 1,5-dihydro-pyrazolo[34-D]-pyrimidinone derivatives |
US6723719B1 (en) | 1997-04-25 | 2004-04-20 | Pfizer Inc | Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3′,5′—monophosphate phosphodiesterase (cGMP PDE5) for the treatment of sexual dysfunction |
US6916927B2 (en) | 1997-04-25 | 2005-07-12 | Pfizer Inc. | Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3′,5′-monophosphate phosphodiesterase (cGMP-PDE5) for the treatment of sexual dysfunction |
US6500610B1 (en) | 1997-05-30 | 2002-12-31 | Cell Pathways, Inc | Methods for identifying compounds for inhibiting of neoplastic lesions, and pharmaceutical compositions containing such compounds |
US6156528A (en) * | 1997-05-30 | 2000-12-05 | Cell Pathways, Inc | Methods for using a phosphodiesterase in pharmaceutical screening to identify compounds for treatment of neoplasia |
US6235742B1 (en) | 1997-10-24 | 2001-05-22 | Pfizer Inc. | 5-substituted pyrazolo[4,3-D]pyrimidin-7-ones |
CN100430396C (en) * | 1997-11-12 | 2008-11-05 | 拜耳医药保健股份公司 | 2-phenyl-substituted imidazo-triazone used as phosphodiesterase inhibitor |
HRP20020585B1 (en) * | 1997-11-12 | 2013-02-28 | Bayer Schering Pharma Aktiengesellschaft | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors |
WO1999024433A1 (en) * | 1997-11-12 | 1999-05-20 | Bayer Aktiengesellschaft | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors |
ES2194567A1 (en) * | 1997-11-12 | 2003-11-16 | Bayer Ag | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors |
US6890922B2 (en) | 1997-11-12 | 2005-05-10 | Bayer Healthcare Ag | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors |
US7314871B2 (en) | 1997-11-12 | 2008-01-01 | Bayer Aktiengesellschaft | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors, for treatment of hypertension |
US7122540B2 (en) | 1997-11-12 | 2006-10-17 | Bayer Healthcare Ag | 2-Phenyl substituted imidazotriazinones as phosphodiesterase inhibitors |
US6566360B1 (en) | 1997-11-12 | 2003-05-20 | Bayer Aktiengesellschaft | 2-phenyl substituted imidatriazinones as phosphodiesterase inhibitors |
US7704999B2 (en) | 1997-11-12 | 2010-04-27 | Bayer Schering Pharma Aktiengesellschaft | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors |
US6362178B1 (en) | 1997-11-12 | 2002-03-26 | Bayer Aktiengesellschaft | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors |
EP1174431A3 (en) * | 1997-11-12 | 2002-01-30 | Bayer Aktiengesellschaft | 2-Phenyl-substituited Imidazotriazinones as Phoshodiesterase Inhibitors |
US7696206B2 (en) | 1997-11-12 | 2010-04-13 | Bayer Schering Pharma Aktiengesellschaft | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors |
GB2346877B (en) * | 1997-11-12 | 2001-12-05 | Bayer Ag | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors |
GB2346877A (en) * | 1997-11-12 | 2000-08-23 | Bayer Ag | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors |
US5852035A (en) * | 1997-12-12 | 1998-12-22 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure to substituted N- arylmethyl and heterocyclmethyl-1H-pyrazolo (3,4-B) quinolin-4-amines |
US6046199A (en) * | 1998-01-14 | 2000-04-04 | Cell Pathways, Inc. | Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B]indole derivatives |
US7115647B2 (en) | 1998-01-14 | 2006-10-03 | Osi Pharmaceuticals, Inc. | Method of inhibiting neoplastic cells with indole derivatives |
US5942520A (en) * | 1998-01-27 | 1999-08-24 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells by exposure to substituted N-cycloalkylmethyl-1-H-pyrazolo (3,4-B) quinolone-4 amines |
US5990117A (en) * | 1998-04-15 | 1999-11-23 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure to quinazoline derivatives |
US6251904B1 (en) | 1998-04-20 | 2001-06-26 | Pfizer Inc. | Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction |
US6458951B2 (en) * | 1998-04-20 | 2002-10-01 | Pfizer Inc | Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction |
EP1085871A4 (en) * | 1998-06-08 | 2001-10-04 | Bristol Myers Squibb Co | QUINAZOLINONE INHIBITORS OF cGMP PHOSPHODIESTERASE |
EP1085871A1 (en) * | 1998-06-08 | 2001-03-28 | Bristol-Myers Squibb Company | QUINAZOLINONE INHIBITORS OF cGMP PHOSPHODIESTERASE |
US6180629B1 (en) | 1998-08-14 | 2001-01-30 | Cell Pathways, Inc. | [4,5]-Fused-1,3-disubstituted-1,2-diazine-6-one derivatives with nitrogen containing substitutents in position one for the treatment of neoplasia |
US6268372B1 (en) | 1998-09-11 | 2001-07-31 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones |
US6124303A (en) * | 1998-09-11 | 2000-09-26 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure to 9-substituted 2-(2-N-aloxyphenyl) purin-6-ones |
US6440981B1 (en) | 1998-09-11 | 2002-08-27 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones |
EP1113796A1 (en) * | 1998-09-16 | 2001-07-11 | Bristol-Myers Squibb Company | FUSED PYRIDINE INHIBITORS OF cGMP PHOSPHODIESTERASE |
EP1113796A4 (en) * | 1998-09-16 | 2003-07-30 | Bristol Myers Squibb Co | FUSED PYRIDINE INHIBITORS OF cGMP PHOSPHODIESTERASE |
US6200771B1 (en) | 1998-10-15 | 2001-03-13 | Cell Pathways, Inc. | Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia |
US6670366B1 (en) | 1998-10-23 | 2003-12-30 | Pfizer Inc | Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction |
JP2000128884A (en) * | 1998-10-23 | 2000-05-09 | Pfizer Inc | PYRAZOLOPYRIMIDINONE cGMPPDE5 INHIBITOR FOR THERAPY OF SEXUAL FUNCTIONAL DISORDER |
US6333330B1 (en) | 1998-10-23 | 2001-12-25 | Pfizer Inc. | Pyrazolopyrimidinone CGMP PDE5 inhibitors for the treatment of sexual dysfunction |
EP0995751A3 (en) * | 1998-10-23 | 2000-10-18 | Pfizer Inc. | Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction |
US6407114B1 (en) | 1998-10-23 | 2002-06-18 | Pfizer Inc. | Pyrazolopyrimidinone CGMP PDE5 inhibitors for the treatment of sexual dysfunction |
EP0995751A2 (en) * | 1998-10-23 | 2000-04-26 | Pfizer Inc. | Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction |
US6133271A (en) * | 1998-11-19 | 2000-10-17 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives |
US6797701B2 (en) | 1998-11-19 | 2004-09-28 | Pfizer Inc. | Antiparasitic formulations |
US6187779B1 (en) | 1998-11-20 | 2001-02-13 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives |
US6369092B1 (en) | 1998-11-23 | 2002-04-09 | Cell Pathways, Inc. | Method for treating neoplasia by exposure to substituted benzimidazole derivatives |
US6077842A (en) * | 1998-11-24 | 2000-06-20 | Cell Pathways, Inc. | Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives |
US6486155B1 (en) | 1998-11-24 | 2002-11-26 | Cell Pathways Inc | Method of inhibiting neoplastic cells with isoquinoline derivatives |
US6034099A (en) * | 1998-11-24 | 2000-03-07 | Cell Pathways, Inc. | Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones |
US6225315B1 (en) | 1998-11-30 | 2001-05-01 | Pfizer Inc | Method of treating nitrate-induced tolerance |
US6177471B1 (en) | 1999-01-29 | 2001-01-23 | Cell Pathways, Inc. | Method for treating patients with acne by administering a CGMP-specific PDE inhibitor |
US6020379A (en) * | 1999-02-19 | 2000-02-01 | Cell Pathways, Inc. | Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia |
US7235625B2 (en) | 1999-06-29 | 2007-06-26 | Palatin Technologies, Inc. | Multiple agent therapy for sexual dysfunction |
US6130053A (en) * | 1999-08-03 | 2000-10-10 | Cell Pathways, Inc. | Method for selecting compounds for inhibition of neoplastic lesions |
US6756373B1 (en) | 1999-10-11 | 2004-06-29 | Pfizer Inc. | Pharmaceutically active compounds |
US6677335B1 (en) | 1999-10-11 | 2004-01-13 | Pfizer Inc | Pharmaceutically active compounds |
US7176311B2 (en) | 1999-10-11 | 2007-02-13 | Pfizer Inc. | Process for preparing pharmaceutically active compounds |
AU779761C (en) * | 1999-10-12 | 2005-09-22 | Lilly Icos Llc | Medicament for treatment of neuropathies |
WO2001026659A1 (en) * | 1999-10-12 | 2001-04-19 | Lareida Juerg | Medicament for treatment of neuropathies |
US7338955B1 (en) | 1999-10-12 | 2008-03-04 | Lilly Icos Llc | Medicament for treatment of neuropathies |
AU779761B2 (en) * | 1999-10-12 | 2005-02-10 | Lilly Icos Llc | Medicament for treatment of neuropathies |
US6555547B1 (en) | 2000-02-28 | 2003-04-29 | Cell Pathways, Inc. | Method for treating a patient with neoplasia by treatment with a vinca alkaloid derivative |
US6569638B1 (en) | 2000-03-03 | 2003-05-27 | Cell Pathways, Inc | Method for screening compounds for the treatment of neoplasia |
EP1365806A2 (en) * | 2000-04-19 | 2003-12-03 | Johns Hopkins University | Use of no acttivators for treatment and prevention of gastrointestinal disorders |
US6548508B2 (en) | 2000-10-20 | 2003-04-15 | Pfizer, Inc. | Use of PDE V inhibitors for improved fecundity in mammals |
US7560564B2 (en) | 2001-03-05 | 2009-07-14 | E.I. Du Pont De Nemours And Company | Heterocyclic diamide invertebrate pest control agents |
JP2004521924A (en) * | 2001-03-05 | 2004-07-22 | イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー | Heterocyclic diamide invertebrate pest control agent |
US8058305B2 (en) | 2001-12-20 | 2011-11-15 | Merck Serono Sa | Pyrrolidine derivatives as prostaglandin modulators |
WO2003053923A2 (en) | 2001-12-20 | 2003-07-03 | Applied Research Systems Ars Holding N.V. | Pyrrolidine derivatives as prostaglandin modulators |
US7635713B2 (en) | 2001-12-20 | 2009-12-22 | Laboratoires Serono Sa | Pyrrolidine derivatives as prostaglandin modulators |
US7335680B2 (en) | 2001-12-20 | 2008-02-26 | Laboratoires Serono Sa | Pyrrolidine derivatives as prostaglandin modulators |
WO2003064402A1 (en) | 2002-01-31 | 2003-08-07 | Pfizer Limited | Treatment of male sexual dysfunction |
US6867320B2 (en) | 2002-02-21 | 2005-03-15 | Asahi Kasei Pharma Corporation | Substituted phenylalkanoic acid derivatives and use thereof |
US8629173B2 (en) | 2002-03-20 | 2014-01-14 | Celgene Corporation | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
US7427638B2 (en) | 2002-03-20 | 2008-09-23 | Celgene Corporation | (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione:, and methods of synthesis and compositions thereof |
US11260046B2 (en) | 2002-03-20 | 2022-03-01 | Amgen Inc. | (+)-2-[1-(3-Ethoxy-4- methoxyphenyl)-2-methylsulfonylethyl]- 4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
US7507759B2 (en) | 2002-03-20 | 2009-03-24 | Celgene Corporation | Methods of using(+)-2-[1-(3-ethoxy-4methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3,-dione |
US7358272B2 (en) | 2002-03-20 | 2008-04-15 | Celgene Corporation | Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4 acetylaminoisoindoline 1,3-dione |
US11040024B2 (en) | 2002-03-20 | 2021-06-22 | Amgen Inc. | Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
US10610516B2 (en) | 2002-03-20 | 2020-04-07 | Amgen Inc. | Methods of using (+)- 2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1, 3-dione |
US10092542B2 (en) | 2002-03-20 | 2018-10-09 | Celgene Corporation | Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
US9724330B2 (en) | 2002-03-20 | 2017-08-08 | Celgene Corporation | Methods of using (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
US9433606B2 (en) | 2002-03-20 | 2016-09-06 | Celgene Corporation | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
US7659302B2 (en) | 2002-03-20 | 2010-02-09 | Celgene Corporation | Methods of using (+)-2-[1-(3-ethoxy-4 methoxyphenyl)-2-methylsulfonylethyl]-4 acetylaminoisoindoline 1,3-dione |
US7659303B2 (en) | 2002-03-20 | 2010-02-09 | Celgene Corporation | Methods of using (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4- acetylaminoisoindoline-1,3-dione |
US9283207B2 (en) | 2002-03-20 | 2016-03-15 | Celgene Corporation | Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
US7276529B2 (en) | 2002-03-20 | 2007-10-02 | Celgene Corporation | Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
US9018243B2 (en) | 2002-03-20 | 2015-04-28 | Celgene Corporation | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
US8802717B2 (en) | 2002-03-20 | 2014-08-12 | Celgene Corporation | Methods of treating arthritic conditions using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline 1,3-dione |
US8455536B2 (en) | 2002-03-20 | 2013-06-04 | Celgene Corporation | Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline 1,3-dione |
US7893101B2 (en) | 2002-03-20 | 2011-02-22 | Celgene Corporation | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
US6962940B2 (en) | 2002-03-20 | 2005-11-08 | Celgene Corporation | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
US7208516B2 (en) | 2002-03-20 | 2007-04-24 | Celgene Corporation | Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
US8093283B2 (en) | 2002-03-20 | 2012-01-10 | Celgene Corporation | Solid forms comprising (+)-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisinoline-1,3-dione, compositions thereof, and uses thereof |
US8273876B2 (en) | 2002-07-16 | 2012-09-25 | Bayer Intellectual Property Gmbh | Medicaments containing vardenafil hydrochloride trihydrate |
US8841446B2 (en) | 2002-07-16 | 2014-09-23 | Bayer Intellectual Property Gmbh | Medicaments containing vardenafil hydrochloride trihydrate |
US6914160B1 (en) | 2002-08-28 | 2005-07-05 | Pfizer Inc | Oxytocin inhibitors |
US7323462B2 (en) | 2002-12-10 | 2008-01-29 | Pfizer Inc. | Morpholine dopamine agonists |
US7902188B2 (en) | 2002-12-10 | 2011-03-08 | Pfizer Inc. | Morpholine dopamine agonists |
US7576081B2 (en) | 2002-12-10 | 2009-08-18 | Pfizer Inc. | Morpholine dopamine agonists |
EP2196201A2 (en) | 2002-12-13 | 2010-06-16 | Warner-Lambert Company LLC | Combination of an alpha-2-delta ligand with a pdev inhibitor or a muscarinic antagonist to treat lower urinary tract symptoms |
US7262192B2 (en) | 2003-04-29 | 2007-08-28 | Pfizer Inc. | Substituted pyrazolo[4,3-d]pyrimidines and their use as PDE-5 inhibitors |
US7470807B2 (en) | 2003-08-14 | 2008-12-30 | Asahi Kasei Pharma Corporation | Substituted arylalkanoic acid derivatives and use thereof |
US7291640B2 (en) | 2003-09-22 | 2007-11-06 | Pfizer Inc. | Substituted triazole derivatives as oxytocin antagonists |
US7875615B2 (en) | 2003-09-22 | 2011-01-25 | Pfizer Inc | Substituted triazole derivatives as oxytocin antagonists |
US7649003B2 (en) | 2003-09-22 | 2010-01-19 | Pfizer Inc. | Substituted triazole derivatives as oxytocin antagonists |
US8097621B2 (en) | 2003-11-24 | 2012-01-17 | Pfizer Inc. | Pyrazolo[4,3-d]pyrimidines as phosphodiesterase inhibitors |
US7572799B2 (en) | 2003-11-24 | 2009-08-11 | Pfizer Inc | Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors |
US7569572B2 (en) | 2004-04-07 | 2009-08-04 | Pfizer Inc | Pyrazolo[4,3-D]pyrimidines |
US8796288B2 (en) | 2005-05-12 | 2014-08-05 | Pfizer Inc. | Anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide |
US8796287B2 (en) | 2005-05-12 | 2014-08-05 | Pfizer Inc. | Anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide |
US8227475B2 (en) | 2005-05-12 | 2012-07-24 | Pfizer Inc. | Anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide |
US8697875B2 (en) | 2008-12-23 | 2014-04-15 | The Trustees Of Columbia University In The City Of New York | Phosphodiesterase inhibitors and uses thereof |
US9974782B2 (en) | 2008-12-23 | 2018-05-22 | The Trustees Of Columbia University In The City Of New York | Phosphodiesterase inhibitors and uses thereof |
US9422242B2 (en) | 2008-12-23 | 2016-08-23 | The Trustees Of Columbia University In The City Of New York | Phosphodiesterase inhibitors and uses thereof |
WO2013067309A1 (en) | 2011-11-04 | 2013-05-10 | Xion Pharmaceutical Corporation | Methods and compositions for oral administration of melanocortin receptor agonist compounds |
US10300042B2 (en) | 2014-06-23 | 2019-05-28 | Celgene Corporation | Apremilast for the treatment of a liver disease or a liver function abnormality |
US10981916B2 (en) | 2016-12-28 | 2021-04-20 | Dart Neuroscience, Llc | Substituted pyrazolopyrimidinone compounds as PDE2 inhibitors |
US11434247B1 (en) | 2017-11-27 | 2022-09-06 | Dart Neuroscience Llc | Substituted furanopyrimidine compounds as PDE1 inhibitors |
Also Published As
Publication number | Publication date |
---|---|
GB9121028D0 (en) | 1991-11-13 |
PT100915A (en) | 1993-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1993007149A1 (en) | Pyrazolopyrimidinone antianginal agents | |
EP0526004B1 (en) | Pyrazolopyrimidinone antianginal agents | |
US5719283A (en) | Intermediates useful in the synthesis of pyrazolopyrimidinone antianginal agents | |
EP0463756B1 (en) | Pyrazolopyrimidinone antianginal agents | |
EP0628032B1 (en) | Quinazolinone antianginal agents | |
US5591742A (en) | Pyridopyrimidinone antianginal agents | |
EP0647227B1 (en) | Purinone antianginal agents | |
WO1993006104A1 (en) | Pyrazolopyrimidinone antianginal agents | |
EP0636626A1 (en) | Pyrazolopyrimidine Derivatives | |
US5734053A (en) | Purinone antianginal agents | |
HU211646A9 (en) | Pyrazolopyrimidinone antianginal agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA FI JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |